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Mycobacterium tuberculosis infection and disease: an overview 
 
Mycobacteria belongs to Mycobacterium tuberculosis complex (MTBC), which includes the 
species Mycobacterium tuberculosis (Mtb), M.bovis, M.bovis BCG, M. africanum (1). These 
species are the causative agents of tuberculosis (TB), one of the most prevalent and severe 
infectious diseases worldwide. Potentially, TB is a lethal disease, but curable if properly 
treated. Factors that lead to a higher risk of transmission among people include HIV. 
Moreover, HIV co-infection dramatically increases the risk of transition from latent 
infection to active TB at least 20-30 times. Other factors for TB incidence include: country 
of birth, malnutrition, active and passive smoking, the use of immunosuppressive drugs (2) 
and type-II diabetes mellitus have a 1.5-fold increased risk of developing TB (3). In the 
poorest country HIV represent the strongest risk factor, whereas the increased prevalence of 
type-II diabetes mellitus mainly contributes to TB epidemics in developing countries (4). 
According to WHO, in 2014 6 million new cases of TB were reported (5). An estimated 9.6 
million people developed TB (5.4 million men, 3.2 million women and 1.0 million children) 
and 63% (fewer than two-thirds) of these people became ill. Based on this report we can 
conclude that 37% of new cases were undiagnosed or were not reported. Furthermore, in the 
group of 9,6 million people who developed TB in 2014, more than half (58%) were infected 
in the South-East Asia and Western Pacific Regions. One quarter (28%) of patients in the 
African Region also had the highest rates of lethal cases relative to population (Figure I1). 
In 2014 TB killed 1.5 million people. Among them 1.1 million people (12% of the 9.6 
million TB cases) were HIV-negative and 0.4 million HIV-positive. In Africa about four out 
of five TB patients (75%) were HIV-positive. As stated in WHO report 2015, TB now ranks 
alongside HIV as a leading cause of death worldwide (Figure I2). 
 
 
 
  
 7 
 
 
Figure I1: Estimated TB incidence rates in 2014. The number of incident TB cases relative to population 
size varies widely among countries. The lowest rates were found predominantly in high-income countries 
including most countries in western Europe, Canada, the United States of America, Australia and New 
Zealand. Oppositely, the higher rates was found in African regions (WHO 2015). 
 
 
 
  
Figure I2: HIV prevalence in new and relapse TB cases in 2014. The proportion of TB cases co-infected 
with HIV was highest in Africa. Notable, more than 50% of TB-, HIV-positive patients were diagnosed in the 
Southern Africa (WHO 2015). 
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The TB disease originates in the ancient past. According to an article of The American 
Journal of Physical Anthropology published in 2008 by Kappelman J. et al., the earliest 
evidences of TB dates back to almost 500,000 years ago, although it is generally believed 
that the TB disease broke out only several thousand years ago (6). The researchers were able 
to characterize small lesion in an ancient fossilized skull belonging to a young Homo erectus 
found in western Turkeyas typical for Leptomeningitis tuberculosa, a form of TB that 
attacks the meningeal structures. With respect to TB epidemiology it should be pointed out 
that Homo erectus was the first human species to migrate out of Africa, gradually adapting 
to different climatic conditions.  
Comas et al. in an article published in Nature Genetics in 2013 analyzed the genomes of 259 
MTBC strains and indicated that TB disease emerged about 70,000 years ago in Africa and 
expanded as a consequence of increases in human population density during the Neolithic 
period (7). Avicenna in the 10th century was the first physician who identified pulmonary 
TB as an infectious disease, recognized the association with diabetes and suggested that TB 
could spread through contact with soil and water. He also developed the method of 
quarantine to limit the spread of tuberculosis. TB became epidemic in medieval Europe and 
was known as “white plague” or “consuption” because it seemed to consume people with 
bleeding from the mouth, fever, pale skin and a long decay. Due to the variety of symptoms, 
TB was not identified as a single disease until about 1820 (8). The causative agent of TB, 
Mycobacterium tuberculosis, was identified and described in 1882 by Robert Koch who was 
awarded the nobel prize in 1905 for this discovery. 
 
Pathogenesis of tuberculosis 
TB infection begins when the mycobacteria reach the pulmonary alveoli, where they invade 
and replicate within alveolar macrophages. The common transmission is by direct human-to-
human spread usually by inhalation of mucous droplets that become airborne when infected 
individual coughs, sneezes, speaks, or even breathes. The bacilli can remain in the air for 
prolonged periods of time, and can even survive for days to months if protected from 
sunlight (9, 10). Cutaneous-mucous contact of skin lesions or mucous membranes with 
infectious material as well as the indirect transmission through contaminated objects is 
another way of infection. The infection is possible as long as the bacilli continue to be 
present in the secretions of the infected patient. Sometimes in patients untreated or 
inadequately treated, the infectious period can last for years. The severity of infectiousness 
depends essentially on the number of tubercle bacilli issued (infectious load) and their 
virulence.  
The Mtb that entered the body through the respiratory route, initially forms the primary 
complex which leads to a local outbreak with exudative character. Primary TB establishes in 
the parenchyma of the lung where the organisms lodge the inflammatory reaction. 
Immediately, the released bacteria are taken up by activated resident lung alveolar 
macrophages which try to engulf and destroy them. Mtb-infected macrophages can be 
themself engulfed by uninfected macrophages through a dedicated apoptotic cell engulfment 
process called efferocytosis (11). This prevent dissemination of infection and reduce 
viability of intracellular mycobacteria. 
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Lung dendritic cells (DC) that encountered Mtb become infected as well. When they engulf 
pathogens they migrate to draining lymph nodes to prime or boost specific T cells, and this 
way leads to the production and secretion of antimicrobial peptides, cytokines, chemokines. 
On the other hand, the tubercle bacillus has the ability to evade the innate response through 
release of the chordal factor to inhibit macrophages activities. The chordal factor is a 
particular derivative of mycolic acids present in the mycobacterium’s membrane, which 
blocks the merger of the phagosome with the lysosome, the action of the lytic enzymes 
contained in it, and the activation of the enzyme complexes that produce highly reactive 
molecules able to eliminate the foreign agent. As a consequence, the macrophage won’t be 
able to eliminate the pathogen, but it will enhance its cytocidal activity. 
The bacterial persistence within macrophages results in the activation of a cell-mediated 
immune response. Both CD4+ T helper 1 (Th1) cells and CD8+ T cells are fundamental in 
protection against TB (12). In particular, CD4+ T lymphocytes activated by MHC class II 
molecules expressed by DC produce cytokines as IFN, TNF, IL-2, lymphotoxin (LT) and 
chemokines that are capable of activating other cellular components. IL-2 acts as an 
autocrine growth factor, whereas LT and TNF induce the activation of neutrophils. IFN 
enables macrophages to enhance phagocytosis and microbicidal activity in the 
phagolysosome. Finally, chemokines recruit other cells, including monocytes, at the site of 
inflammation. 
Additionally, CD8+ T cells are also activated after recognition of peptides associated with 
MHC class I molecules. The activated CD8+ T lymphocytes differentiate to cytotoxic 
lymphocytes (CTL) and are able to produce cytokines and cytolytic molecules. Thus, they 
selectively eliminate any cell expressing the foreign antigen, including phagocytic cells 
containing replicating mycobacteria. 
Inflammatory cells involved in immune response against Mtb evolve into a well organized 
structure known as granuloma. The central part of the granuloma is formed by bacilli, 
epithelioid cells and death macrophages with Langhans giant cells that form an epitelioid 
layer, similar to the epithelium. More externally, T and B lymphocytes, fibroblasts and 
connective tissue surround this specific structure and form a kind of capsular layer. T cells 
and CD1-restricted T cells are also involved (13, 14). Adhesion to the extracellular matrix 
(ECM) is essential for the recruitment and retention of T cell, B cells and macrophages 
during formation of granuloma. T cells use integrins for adhesion while fibronectin is a 
major component of ECM engaged in the process (15). The main function of the granuloma 
is to avoid the dissemination of bacteria by isolation of the mycobacteria from the rest of the 
lung, and to localize bacteria within this structure for the action of the immune system. 
However, granuloma formation can cause tissue damage that might lead to the loss of 
function in involved organ. Therefore, on the one side the established immune response is 
important to stop the dissemination of bacteria, but on the other side an excessive and 
uncontrolled activation of the immune system cause tissue damage that results in the 
impaired body’s function. 
Infected individuals usually develop active TB one or two years after infection. Infection 
does not necessarily lead to active pulmonary TB. In more than 90% of subjects infection 
remains in a subclinical stage known as latent TB infection (LTBI). During LTBI the 
pathogen lasts in a quiescent state in which only non- or slowly replicating Mtb bacilli are 
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present (16). Mtb may persist for decades in the lymph nodes and in some cases in latent 
infected individuals a reactivation of TB infection can occur. Risk factors for reactivation of 
TB are socio-economic or behavioral factors, age, gender, the concomitant presence of other 
disease such as diabetes mellitus, HIV, or diseases in which patients need 
immunosuppressive anti-TNF antibodies treatment such as rheumatoid arthritis, psoriasis 
and Crohn’s disease. This emphasizes the important role of the immune system in 
suppressing reactivation and replication of mycobacteria (17). There is a constant battle 
between Mtb and host immune system. 
In rare cases, tubercle bacilli from the primary complex spread via the bloodstream and 
lymphatic system to many parts of the body, especially if a pulmonary TB is not properly 
treated or in immunodeficiency conditions. This form of TB disease is known as 
extrapulmunary TB. In this case, bacteria most commonly resides in the apices of the lungs, 
liver, spleen, meninges, peritoneum, lymph nodes, pleura, and bone. Extrapulmonary TB can 
develop either in localized or disseminated forms (miliary TB, see Figure I3). The most 
severe form of extrapulmonary TB is TB meningitis that is lethal in most of the cases. 
 
 
 
Figure I3: Mtbtransmission and outcome.TB is transmitted through airborne particles containing the 
"droplet nuclei" of the mycobacteria, which are released by a person with infectious TB during coughing, 
sneezing or simply talking. Host can respond to Mtb infection in several ways.If the immune system of 
infected individual manages immediate killing of Mtb disease is asymptomatic. An about 10% of individuals 
infected withMtb develop active TB (primary TB). A significant proportion of affected peopleharbors Mtband 
develops latent TB infection (LTBI). These individual have about 5-10% risk of TB reactivation form the 
latent state. The mycobacteria can however attack any organ via bloodstream resulting in extrapulmonary TB. 
 
 
Tuberculosis therapy and vaccination 
Efficient drugs against TB were first developed in the 1940s (5, 8). The most effective first-
line anti-TB drug, rifampicin, became available inthe 1960s. The currently recommended 
therapeutic strategy by WHO for new cases of drug-susceptible TB isa combination of four 
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first-line drugs:isoniazid, rifampicin, ethambutol and pyrazinamide. The course of TB 
treatment usually takes four/six months in which rapidly killing of massive number of 
bacteria occurs. The prolonged therapy prevents the development of multi-drug resistent 
mutants and effectively sterilizesof the local infection site. Most recently, WHO 
reportedsuccessful treatment in 85% of new TB cases (5). 
Treatment for multidrug-resistant TB (TB resistant to the two most powerful anti-TB drugs 
isoniazid and rifampicin;MDR-TB) requires more expensive and more toxic drugs. This is 
they reason why patients often fail to complete the therapy. Globally, in 2014, an estimated 
190 000 people died of MDR-TB. More TB patients were diagnosed for drug resistance in 
2014 than ever before. A total of 111 000 people started alternative MDR-TB treatment in 
2014, which gives an increaseof 14% compared with previous year (Figure I4). 
 
 
 
Figure I4: New TB cases with MDR-TB.Eastern European and Central Asian countries have the highest 
levels of MDR-TB. Levels of drug resistance among new cases remain low (<3%) in many parts of the world, 
including many countries in Americas, majority of African countries, most of the South-East Asia Region, 
most of Western Europe, several countries in the Western Pacific Region (WHO 2015). 
 
 
According to the previously reported WHO analysis, it’s clear that although effective drug 
treatments are avalaible in tackling TB disease, TB nevertheless kills about 4000 people 
every day so a vaccine that would prevent infection and/or disease is an essential component 
in the fight against TB with a view to both the containment of infection and the complete 
elimination of the pathogen worldwide. 
Historically, the major purpose of most immunization programs was to obtain high antibody 
titers in vaccinated subjects.The first attempts to TB control through vaccination started at 
the end of 1800, just after the identification of the bacillus by Robert Koch, but it was the 
live attenuated vaccine by Albert Calmette and Camille Guérin (BCG) to dominate in next 
century. 
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In 1908, Guérin and Calmette were dedicated to the finding of an effective vaccine against 
TB from a virulent strain of Mycobacterium bovis, the etiologic agent of TB in cattle, which 
is closely related to Mtb, having a homology greater than 90%. Thirteen years later they 
created an attenuated bacillus which was proved safe and effective in preventing the 
development of the TB disease. Since 1921 the BCG vaccine has been introduced for human 
purpose. At the beginning the result of BCG vaccination in the human population was 
controversial. Up to date M. bovis BCG-vaccination protects infants from dissemination of 
TB, particularly TB-meningitis (18,19) but no efficacy was demonstrated against pulmonary 
TB in adults.  
In addition, like all live-attenuated vaccines, its use is not adviced in immunosuppressed 
patients, in particular in HIV+ subjects for which there is an increased risk of developing 
severe clinical forms of tuberculosis. Despite the many negative aspects related to the 
vaccine, the BCG is still widely used.  Until now, no new effective vaccine against TB are 
avalaible.  
There have been several attempts to explain the variable protective efficacy of BCG.The 
insufficient level of protection obtained with BCG may be explained in part by the lack of 
effective stimulation of T lymphocytes, in particular CTLs by the attenuated bacillus. The 
heterogeneity of the strains used was suggested as another possible explanation in the 
variability of the results obtained in different clinical trials.  
Behr and Small have shown that, during the process of attenuation of M. bovis numerous 
genes potentially relevant in the induction of an effective immune response directed against 
the Mtb are lost (20). In particular, they identified a region of about 9.5 kb named RD1 
(Delete Region 1)in the genome of the virulent strain, that is absent in the bacillus Calmette-
Guerin. The genes present in this region are responsible for the synthesis of antigenic 
determinants important for the activation of T lymphocytes such as the immunodominant 
protein ESAT-6. 
In conclusion, one fourth of the global population is infected with Mtb, and the vast majority 
of them do not develop active TB disease indicating a stable coexistence between Mtb and 
human host. The disease outcome depends on pathogen, host and environmental factors. 
Although effective TB drugs and vaccination are avalaible, MDR-TB strain, HIV co-
infection, the lack of BCG efficacy make TB control still far from reach. An effective TB 
vaccine development is necessary and depends on a detailed understanding of the 
mechanism underlying the host immune response to Mtb. 
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Outline of this thesis 
 
Protection against Mtb infection depends on the cellular immune system, involving many 
subsets both of innate and adaptative immunity. Upon exposure to Mtb in the airways, a 
series of immune responces are triggered. At first macrophages become activated. Then, 
DCs migrate to draining lymph nodes where they prime and boost specific T cell. Finally, 
several subsets of T cells get involved such as: Th1 and Th17 CD4+ T cells, regulatory T 
cells (Tregs), CD8+ T cells,  T cells and CD1-restricted T cells. These subsets cooperate 
and/or interfere with each other to control infection, and carry out inflammatory as well as 
regulatory activities that maintain immunological homeostasis.  
This thesis aims to analyze the specific contribution of different T cell subsets in the control 
of TB infection, with particular attention to HLA-E restricted CD8 T cells which are a new 
player in the adaptive immune response to Mtb. 
 
Chapter 1 summarizes our current knowledge on the immune response in human TB and 
focuses on the role of different functional signatures of T cell subsets in the immune 
response to Mtb infection. The role of the “conventional” subsets of CD4 and CD8 T cells 
will be discussed as well as the role of other “non coventional” subsets. The protective role 
of Mtb-specific-CD4+ Th1-type polyfunctional T cell responses will be discussed. 
Antigens specific CD8+ T cells may also produce Th1-type cytokines as well and cytotoxic 
molecules that directly kill mycobacteria causing apoptosis of target cells. Moreover, it has 
been recently reported that CD8 T cells with a “multifunctional”profile can be a better 
markers of protection than CD4+ T cells. Although, they cannot compensate for the lack of 
CD4+ T cells, there is a special interest in studying CD8 T cells that are either MHC-class Ia 
or MHC-class Ib-restricted. These studies include the role of HLA-E-restricted cells, lung 
mucosal-associated invariant T cells (MAIT), Stem Memory T cell (Tscm) and CD1-
restricted cells.  
 
In Chapter 2 HLA-E restricted CD8+ T cells were studied in detail. We have characterized 
this specific subset as anadditional type of effector cells playing a role in immune response 
to Mtb during active infection. HLA-E restricted CD8+ T cells from TB patients recognize 
Mtb-peptides in a CD3/TCR αβ mediated and CD8-dependent manner. HLA-E-restricted 
recognition of Mtb peptides is detectableby a significant enhanced ex vivo frequency of 
tetramer-specific circulating CD8 T cellsduring active TB. These CD8 T cells produce type 
2 cytokines upon antigenic stimulation in vitro, help B cells for antibody production, and 
mediate limited TRAIL-dependent cytolytic and microbicidal activity toward Mtb-infected 
target cells. 
The Chapter 3 reports part of the results collected during the one-year internship period 
carried out at the Department of Infectious Disease of the Leiden University Medical 
Centrum (LUMC) directed by Prof. Dr Tom H. M. Ottenhoff. The project is still in progress. 
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Recently the Ottenhoff’s group demonstrated that HLA-E restricted CD8+ T cell clones 
obtained from PBMCs of healthy PPD+donors and recognizing Mtb peptides produce Th2 
cytokines (in particular IL-4, IL-5 and IL-13) instead of the usual Th1 cytokines, exert 
cytolitic or suppressive functions, inhibit mycobacterial growth and are able to activate B-
cells (224). These results as well demonstrate the unique capability of this subset to respond 
in a specific manner after stimulation with the selected HLA-E peptides. The data were 
obtained using different techniques such as intracellular cytokine staining (ICS) for the 
detection of Ag-specific cytokine production, tetramer assay and T cell cloning for 
evaluation of the ex vivo frequency and the functional activities of HLA-E antigen-specific 
CD8+ T cells, in patients in active TB with or without HIV co-infection and in LTBI 
subjects. PPD-  healthy donors were used as control.  
The ex-vivo frequency of MAIT cells was also analyzed.  
 
Chapter 4 reports in detail the material and methods used to perform the experiments 
presented in Chapter 3.  Chapter 4 is followed by a brief discussion analyzing all obtained 
results. 
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Functional signatures of human CD4 and CD8 T cell responces 
to Mycobacterium tuberculosis 
 
Prezzemolo T., Guggino G., La Manna M.P., Di Liberto D., Dieli F., Caccamo N.  
Front Immunol. 2014 Apr 22;5:180. 
 
Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi and Central Laboratory of 
Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy. 
 
 
Introduction 
TB, with approximately 9 million cases annually, determines a world-wide mortality and 
morbidity, especially in low-income countries (21-23). Mtb, the causative agent of TB, is 
transmitted via aerosol droplets that are suspended in the air for prolonged periods of time 
(24), determining a risk of infection to people who inhalate these droplets. However, 
infection does not necessarily lead to TB disease; in fact, as reported in several studies, only 
3–10% of immunocompetent individuals that are infected will develop the disease during 
their life-time (25), while more than 90% of infected subjects contain infection in a 
subclinical stage known as latent TB infection (LTBI), in which the pathogen remains in a 
quiescent state (24). One of the important aspects that can contribute to reactivation depends 
on the immune system of each individual that can be perturbed by several factors during 
life-time, such as chronic diseases: diabetes, alcoholic liver disease, HIV co-infection, and in 
some circumstances, the use of steroids or other immunosuppressive drugs. Another 
occurrence of active disease in later life is attributable to reactivation of latent Mtb bacilli or 
to a new infection with another Mtb strain. However, this huge reservoir contributes to fuel 
the high numbers of new active TB disease (23, 26); therefore, in order to diminish the risk 
of new active TB disease, it is important to treat LTBI cases by chemoprophylaxis, 
successfully eradicating the infection in the majority of cases. LTBI subjects, due to the 
increasing use of biological drugs, such as tumor necrosis factor-α (TNF-α)/Interleukin (IL)-
12/IL-23 blockers for the treatment of inflammatory diseases like rheumatoid arthritis, 
Crohn’s disease, and psoriasis, have major risk to progress toward active disease more than 
other subjects (23, 27). Diagnosis of LTBI remains a priority for TB control within high 
income, low TB prevalence countries (28, 29), where a high proportion of TB cases occurs 
in immigrants from countries with high TB incidence (30, 31). 
The study of subjects that are able to control Mtb infection in the long-term may be 
particularly informative in this respect. Despite two decades of intensified research, the 
mechanisms involved in the protective immune response against Mtb are not well 
understood. So, the comprehension of the pathways involved in protection in the host could 
represent biomarkers useful as correlates of protection, while the inhibition of the pathways 
involved in the surviving of host pathogens, could represent a biological target to contrast 
the bacilli growth and replication (32, 33). 
Mtb involves several conventional and unconventional T cell subsets that are characterized 
by distinct effector functions and surface phenotype markers (34). Th1 CD4 T cells activate 
effector functions in macrophages that control intracellular Mtb, and their role has been 
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correlated with protection (34). Moreover, several studies have reported that Th17 cells, 
which are able to produce IL-17, are involved in immune protection against Mtb, primarily 
due to the effect of this cytokine in attracting and activating neutrophils (34, 35). Th17 cells 
have been involved in protection against TB at early stages (35, 36), for their capacity to 
recruit monocytes and Th1 lymphocytes to the site of granuloma formation (34, 35, 37). On 
the contrary, several studies have demonstrated that unrestricted Th17 stimulation 
determines an exaggerated inflammation mediated by neutrophils and inflammatory 
monocytes that rush to the site of disease causing tissue damage (34, 38–40). 
CD4 T cells recognize antigenic peptides derived from the phagosomal compartment in the 
context of MHC-class II molecules (41). Mtb preferentially resides in the phagosome, where 
mycobacterial Ags can be processed and assembled to MHC-class II molecules (34, 42, 43). 
Another conventional lymphocytes subset, CD8 T cells, contributes to immune protection 
against TB (44): upon specific Ag recognition, CD8 T cells differentiate into effector cells, 
which produce cytolytic molecules and cytokines that kill both host cells and the 
intracellular Mtb (34, 45). 
CD8 T lymphocytes recognize antigenic peptides, which are generally loaded in the 
cytosolic compartment in the context of MHC-class I molecules (41). MHC-class I loading 
can occur because of the intracellular pathogen or Mtb proteins diversification from the 
phagosome to the cytosol (34, 46). Moreover, apoptotic vesicles coming from infected 
macrophages and dendritic cells (DCs) can be uptaken by DCs (47, 48), which, in turn, will 
process and shuttled peptides into the canonical MHC-class I presentation pathway, a 
process termed cross-presentation (49). 
Other cells play a role in the control or in the suppression of immune responses during Mtb 
infection such as Th2 cells, which counter-regulate Th1 cells and likely impair protective 
immunity against TB (50, 51), and regulatory T (Treg) cells (52, 53), which also contribute 
to the down modulation of the immune response to the pathogen (34) and to TB reactivation 
(34, 52–54). 
The so-called unconventional T cells are activated during TB; these cells are able to 
recognize lipids that are abundant in the mycobacterial cell wall, in the context of non-
polymorphic CD1 molecules (55). Very recently, mucosal-associated invariant T cells 
(MAIT) have been found to recognize protein Mtb (Ags) presented by the non-classical 
molecule MR1 (56). γδ T cells, recognize “phosphor Ags” of host or bacterial origin and 
may also contribute to the immune response to Mtb as well (34, 57). Figure F1 shows the 
different cell population involved in the immunopathology of TB. 
In the last years, the potential role of distinct T cell subsets as biomarkers of active TB 
and/or LTBI has been studied. Functional CD4 and CD8 T cell subsets have been defined on 
the bases of cytokine production as single, double, or triple producer cells. These different 
cytokine signatures have been differently associated with disease stage, mycobacterial load 
or treatment, and several studies, mostly derived from vaccination in animals, have 
highlighted that polyfunctional CD4 T cells are associated with protective immunity. In 
contrast, more recent studies have suggested that these cells may be not correlated with 
protection, but rather with TB disease activity (58, 59). 
In this review, we will analyze the complexity of the immune response of conventional CD4 
and CD8 T cells widely described by recent studies in patients with pulmonary and extra-
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pulmonary disease and in subjects with LTBI, in order to better define the potential of 
different functional signatures of T cells as potential biomarkers. 
 
 
Figure F1: Cells involved in immune response during Mtb infection. The figure shows conventional and 
unconventional T cell subsets that contribute to the immune response against Mtb. 
 
 
Population of human memory T cells 
Individuals that have encountered a pathogen, develop an adaptive immune response with 
the induction of memory cells that will recognize the same Ag, upon the second encounter, 
dictating the type of immune response. Several studies have delineated that the quality of the 
memory response is important to dissect the real difference between protection and 
immunopathology, and to design strategies for vaccination (60). 
Generally, the generation of memory T cells is characterized by different phases (61). The 
first encounter with an Ag, defined priming, determines a massive proliferation and clonal 
expansion of Ag-specific T cells followed by a phase of contraction, where the majority of 
these cells, named effector cells, are eliminated by apoptosis (62, 63). During this primary 
response, memory T cells develop and are maintained for extended periods due to several 
mechanisms such as the retention of Ag, stimulation/boosters, or homeostatic proliferation, 
that will insure the maintenance of a pool of cells that can rapidly respond to subsequent 
encounters with the pathogen. 
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The induction of memory T cells by vaccination against intracellular pathogens has 
definitively led a major challenge for the development of new subunit vaccines (60). 
In humans, the functional properties of memory T and B cells can be defined, at least for 
those cells circulating in the blood, using techniques that detect typical surface markers (64). 
The combinatorial expression of surface markers such as adhesion molecules, chemokine 
receptors, and memory markers, allows for tissue specific homing of memory and effector 
lymphocytes and thus provides full characterization of that particular subsets of memory T 
cells, in terms of preferential residence inside tissues (60, 65, 66). 
At least dozens of subsets can be identified and enumerated on the basis of distinct cellular 
functions that express unique combinations of surface and intracellular markers (67). 
Memory T cells could be divided into CD62L+ and CD62L− subsets; moreover some surface 
markers are specific for T cells homing to mucosa and skin that are confined to the CD62L− 
subset (68, 69). The development of techniques that allow to measure cytokines production 
at the single-cell level and the analysis of several surface markers has permitted to correlate 
the functional properties of T cells with their phenotype (70). CCR7+ memory cells are 
named central memory (TCM) cells: they are able to home to secondary lymphoid tissues, 
produce high amounts of IL-2 but low levels of other effector cytokines (71), while their 
CCR7− counter parts, named effector memory (TEM) cells, are able to produce high levels of 
cytokines, exert rapid effector functions and home to peripheral tissues (71). It has been 
established a relationship between TCM and TEM cells suggested by the analysis of the 
telomeres that are longer in TCM than TEM cells and TCM cells are capable of generating TEM 
cells in vitro, but not vice versa (71). Studies performed in humans and rhesus macaques 
both in vitro and in vivo have led to the identification of T cells with multiple stem cell-like 
properties, termed memory T stem cells (TSCM). These cells constitute a relatively rare 
memory population having a largely T naive (TN) phenotype, while overexpressing CD95 
(71, 72), which is usually expressed at high levels by all memory cells (73, 74). TSCMcells, 
precede TCM cells in differentiation. These type of cells are capable of generating all 
memory subsets, including TCM cells (71, 72); no other memory subset thus far has been 
found to regenerate TSCM cells (64). 
Another subset of “transitional” memory T cells (TTM) has been defined, mostly of which 
were isolated in the peripheral blood of healthy individuals (75, 76). These TTM cells are 
more differentiated than TCM cells but not as fully differentiated as TEM cells in terms of 
phenotype (75, 76) and ability to expand in response to IL-15 in vivo (77, 78). 
Very recently, Mahnke et al. propose that the phenotypic, functional, and gene expression 
properties of human memory T cell differentiation follow a linear progression along a 
continuum of major clusters (TN, TSCM, TCM, TTM, TEM, and TTE cells) (64). According to this 
linear progression, memory T cells, progressively acquire or lose their specific functions 
(Figure F2). 
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Figure F2: Human memory T cell subsets. Following encounter with Ag, quiescent T cells develop into 
effectors, whose phenotype is highly dynamic and largely unpredictable. When the Ag is cleared, effector T 
cells that survive return to a quiescent memory state. Cells differentiate from TN to TSCM, TCM, TTM, TEM, and 
culminating in TTE cells. Memory T cells progressively lose or acquire specific functions, such as the ability to 
migrate to peripheral tissues or to proliferate or produce effector molecules. 
 
Other molecules that mediate lymphocyte functions, including markers of migration, co-
stimulation, and cytotoxic molecules and adhesion markers can better define these different 
T cell subsets (Table F1). 
Seder et al. have proposed that T cells progressively acquire their functions with further 
differentiation, until they reach the phase that is adequate for their effector function (such as 
the production of cytokines or cytotoxic activity) (64, 79). The authors have demonstrated 
that the continued antigenic stimulation led to progressive loss of memory potential as well 
as the ability to produce cytokines, until the last step of the differentiation pathway 
represented by effector cells that are able to produce only IFN-γ and are short-lived, named 
terminally differentiated effector cells (TEMRA) (79). Another aspect that can optimize this 
linear differentiation process will depend on the amount of initial Ag exposure or the 
different conditions that are present in the microenvironment, which will dictate the extent 
of differentiation (64, 79). 
Hierarchical expression of cytolytic molecules and surface markers, such as CD27, CD28, 
and CD57, has been delineated for CD8 T cell subsets. Granzyme (GrA) is the first 
cytotoxic molecule detected in memory cells, followed by GrB (GrB) and subsequently by 
perforin (80–82). GrB is always expressed in the presence of GrA, while, perforin+ cells are 
primarily positive for GrA and GrB, making it a choice indicator for cytolytic cells (82). 
Usually, perforin is present in cells that are CD27− and CD28− (83), while this molecule is 
always associated with the expression of the senescence marker CD57, which can be used as 
marker for T cells with high cytolytic potential (64, 82). Finally, the identification of the 
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different subsets of human memory T cells, through the analysis of the expression of 
exclusive markers in that particular population could have a potential implications in T cell-
based immunotherapy for infectious disease or other immune pathological conditions. 
Several studies have evaluated the different distribution of Ag-specific memory T cells 
subsets as good model of correlate of protection; for example, in response to chronic 
infectious agents such as HIV-1, hepatitis C virus (HCV), and Mtb, the increase of the 
frequency of Ag-specific TCM cells, which produce high levels of IL-2, is associated with 
individuals’ ability to control the viral load (84–88). 
Moreover, the response to cytokines used to differentiate or to maintain the different human 
memory T cells has been characterized (89). It has been shown that TEM cells can proliferate 
in response to IL-7 and IL-15 in vitro but do not expand because of spontaneous apoptosis; 
conversely, TCM proliferate and differentiate to TEM cells, in the absence of these cytokines 
(90, 91). 
Therefore, the quality of T cell responses can be modulated by several factors, and it is 
crucial for establishing the disease outcome in the context of various infections or 
pathologies. 
In summary, the definition of the different subsets of memory T cells can be used to 
delineate the quality of a given T cell response, and this can be achieved by the combination 
of cell-surface phenotype, functional properties, and the capacity to traffic to lymphoid and 
non-lymphoid tissues: such a complex analysis should confer more intuition if an immune 
response will be protective or not. 
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Subsets    TN     TSCM    TCM    TTM     TEM     TTE      Category                         Antigen               Function 
 + ++ ++ ++ - - Costimulation/ 
Survival 
CD28 Costimulation 
 ++ + + + -/+ -  CD27 Costimulation 
 ++ +++ +++ ++ -/+ -  CD127 IL-7 signaling 
 - -/+ + ++ + +  PD-1 Inhibition of effector function 
 - + ++ +++ +++ +++  CD122 IL-2/IL-15 signaling 
 + + + + + +  CD132 γc cytokine signaling 
 - ND -/+ + ++ +++  KLRG-1 Inhibition of effector function 
 + ++ ++ +++ +++ +++ Adhesion CD11a Adhesion to APC/endothelium 
 - + ++ +++ +++ +++  CD58 Adhesion to APC 
 -/+ + ++ ++ ++ ++  CD99 Transendothelial migration 
 + + + - - - Migration CD62 L Secondary lymphoid tissues homing 
 - - - - + -  CD103 Gut homing 
 -/+ + ++ +++ +++ -/+  CCR4 Chemokine response/Th2 associated 
 - - + ++ +++ ++  CCR5 Homing to inflamed  tissues 
 - - ++ +++ +++ -  CCR6 Chemokine response/Th17 associated 
CD4 - ND + - - -  CCR9 Gut homing 
CD8 - ND + ++ ++ -    
 - - + ND ++ -  CCR10 Skin homing 
CD4 - -/+ + ++ +++ +++  CXCR3 Homing to inflamed tissues 
CD8 ++ +++ +++ ++ + +    
 + ++ +++ +++ ++ ++  CXCR4 Homing to Bone Marrow 
 - ND + ND ++ ND  CLA Skin homing 
CD4 - - - - -/+ + Cytolitic molecules Granzyme A Cleavage of cellular proteins 
CD8 - - -/+ ++ +++ +++    
CD4 - - - - -/+ -/+  Granzyme B Cleavage of cellular proteins 
CD8 - - - + ++ +++    
CD4 - - - - -/+ -/+  Perforin Pore forming 
CD8 - - -/+ + ++ +++    
Combination of + and – indicate the expression level respect to TN cells. 
ND= not determined. 
 
Table F1:Expression of functional molecules by circulatingT cell subsets. 
 
 
Subsets of Memory CD4 T cells in tuberculosis 
Mtb-specific-CD4+ T cell protective response is typically due to Th1 cells and is mediated 
by IFN-γ and TNF-α that recruit monocytes and granulocytes and promote their anti-
microbial activities (92–94). 
Recent studies have shown that polyfunctional T cells (i.e., T cells equipped with multiple 
effector functions) (64, 95), could exert immune protection toward viral infections such as 
HIV (96, 97), models of TB vaccine (98–101), or in murine models of leishmania (56). 
However, the role of polyfunctional T cells during Mtb infection is controversial and 
different from that observed in chronic viral infections (56, 60, 101). 
The definition of polyfunctional T cells was attributed to their ability to proliferate and to 
secrete multiple cytokines and these cells were found to play a protective role in antiviral 
immunity in chronic infections (when Ag load is low). Conversely, single IFN-γ-secreting 
CD4 and CD8 T cells typically predominate in acute infections (when Ag load is high), and 
in chronic infection characterized by the failure of immune control: in the case of HIV-1 
infection, in fact, the response is dominated by HIV-1-specific-CD4 and -CD8 T cells that 
are able to produce only IFN-γ in both the primary and chronic phases of infection. On the 
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other hand, the distinct cytokines profile during intracellular pathogens infection, comprises 
a very wide spectrum of T cell subpopulations (95). 
Several authors have recently shown that polyfunctional T cells release multiple cytokines 
simultaneously in a relatively short period. The analysis of different aspects that could 
contribute to the release of cytokines, such as the methodologies used to stimulate the cells, 
peptides, or proteins used, the different cohort groups included in the study, should be taken 
into account, considering that very often the results obtained are controversial (95, 102). 
Earlier studies in human TB have investigated on the role of polyfunctional T cells able to 
produce IFN-γ in combination with IL-2 (95, 103–106), and later on, a subset of cells able to 
simultaneously produce IFN-γ, TNF-α, and/or IL-2 was detected in patient with active TB 
disease compared to latently infected individuals (107–110), whose frequency decreased 
after anti-TB treatment. In another study, high frequencies of CD4 T cells expressing three 
cytokines simultaneously (IFN-γ, TNF-α, and IL-2) was found in adults with active TB 
disease, as compared to the frequency found in LTBI subjects, in which IFN-γ single and 
IFN-γ/IL-2 dual secreting CD4 T cells dominated the anti-mycobacterial response. 
Therefore, the presence of multifunctional CD4 T cells in TB patients was associated with 
the bacterial loads, as suggested by their decrease after completion of anti-TB chemotherapy 
(102, 111). This implies that multifunctional CD4 T cells are indicative of active TB rather 
than assuming a protective role. However, during these years, several contrasting findings 
have been reported, which do not allow a clear-cut conclusion on the role of polyfunctional 
CD4 T cells (60). In fact, some authors have found a reduced frequency of polyfunctional T 
cells in patients with active TB disease compared to latently infected individuals, which is 
recovered with the anti-TB therapy (95, 112, 113). Similar recovery of dual IFN-γ/IL-2-
producing cells with the anti-TB therapy was also previously reported (102, 114). 
Finally, a higher proportion of Ag-specific effector memory TEM cells and a decreased 
frequency of TCM CD4
+ T cells has been found in patients with active TB (115, 116), as 
compared to the distribution found in LTBI individuals (95). 
Since it is not possible to associate any specific cytokine profile with protection against 
active TB, recent studies have tried to find a correlation between functional signatures of 
CD4 or CD8 T cells and the state of infection/disease. 
Marin et al. have analyzed the Th1 and Th17 responses through the counts of IFN-γ and IL-
17 producing T cells by elispot assay, the frequencies of polyfunctional T cells producing 
IFN-γ, TNF-α, IL-2, and IL-17 by ICS, and the amounts of the above cited cytokines 
released after 1 day (short term) and 6 days (long-term) of in vitro stimulation using different 
Ags (CFP-10, PPD, or Mtb) (95) by ELISA. The evaluation of different T cell subsets after 
short- and long-term in vitro stimulation with different Ags has permitted to find a 
significant increase in single and double producer CD4+cells in long-term in vitro 
stimulation compared to short term in vitro stimulation in LTBI subjects and a significant 
increase of the frequency of single producer cells in patients with active disease (95). Mtb 
stimulation determined an increase in the frequency of single and triple producer T cells in 
LTBI subjects in 6 days compared to the frequency found in 1 day in vitro stimulated cells, 
with a significant value found for the frequency of double producer T cells in patients with 
active disease (95). These results suggest that the use of different mycobacterial Ags could 
induce distinct T cell functional signatures in LTBI subjects and in patients with active 
disease, highlighting that it is possible to define “functional signatures” of CD4 T cells 
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correlated with the state of infection and that could be used as indicators of the clinical 
activity of the disease (102). 
Very recently, Petruccioli et al. have correlated bifunctional “RD1-proteins”-specific-CD4 T 
cells with effector memory phenotype with active TB disease, while “RD1-proteins”-
specific-CD4 T cells with a central memory phenotype were associated with cured TB and 
LTBI subjects (102). According to this study, the EM phenotype should be associated with 
inactive TB due to the presence of live and replicating bacteria, whereas the contraction of 
this phenotype and the further differentiation toward CM T cells in LTBI and cured TB 
subjects could indicate Mtb control, suggesting that the different expression of the 
memory/effector status may be used to monitor treatment efficacy, as previously suggested 
in patients with active TB with HIV co-infection (102, 117, 118). 
A more detailed study on the role of Ag-specific T cell phenotype and function has been 
carried out by Lalvani et al. who delineated the association of TB disease stage with Mtb-
specific cellular immunity. The authors have found the same trend of functional signature 
demonstrated by Petruccioli, but in response to different antigenic stimulation, namely PPD 
and RD1-peptides: in fact, Ag-specific-CD4 T cells were principally of the CM phenotype in 
subjects with latent infection compared to EM cells predominantly found in patients with 
active disease. Combined measurement of both functional profile and differentiation 
phenotype, in this study, reflects a discriminatory immunological status in the different 
cohort groups studied (patients with active disease vs. LTBI) (119). Moreover, HIV 
infection did not influence the number of Mtb-specific-CD4 effector cells, which instead 
was influenced by TB disease stage. This last aspect could be intriguing for the fact that 
assessment of cellular changes could be used also for immune compromised patients; in fact, 
it is known that HIV and active TB both impact Mtb-specific T cell immunity, such as skin 
test anergy, and therefore, dissection of distinct subsets as biomarkers could have an impact 
also in HIV co-infection. 
Altogether, the above studies highlight the concept that the protective immune response 
against mycobacterial infection seems to depend more on the quality of CD4 T cell response 
assessed as the capacity to exert multiple functions, than on their magnitude, which is due to 
their Ag-specific frequency (64, 95). Finally, several methodologies used for the evaluation 
of the profiles of Mtb-specific-CD4 T cells in the reported studies led to different results: 
these include Ag specificity and type, in vitro stimulation conditions (short- or long-term in 
vitro stimulation), variability of the study cohort characteristics and at least, the monoclonal 
antibodies used to distinguish the subsets of CD4 T cells or intracellular cytokines content 
(60). 
Thus, further studies are necessary to define particular phenotypes of Mtb-specific-CD4 T 
cells, assessing several functional properties such as activation, memory, migratory and 
inhibitory receptors, and ligands. 
 
 
Subsets of CD8 T cells in tuberculosis 
CD8+ T cells contribute to protective response against TB (120, 121). CD8+ T cells 
recognize Ags derived from an intracellular environment and could serve as sensors of 
bacterial burden. In fact, human CD8+ T cells preferentially recognize cells heavily infected 
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with Mtb (122) and in animal models, the magnitude of the CD8 response correlates with 
bacterial load (123–125). 
The mechanisms involved in CD8+ T cell activation during Mtb infection are incompletely 
defined. DCs possess several pathways to load MHC-class I molecules, such as classical 
cytosolic processing, or alternative processing of phagosome located pathogens and 
endosome-located Ags. The recent evidences that virulent mycobacteria can escape from the 
phagosome into the cytoplasm and the possibility to direct access MHC-class I 
processing/presentation pathway provide a new mechanism (47). DCs also can take up 
vesicles derived from apoptotic Mtb-infected cells, after which the Ags are cross-presented 
through MHC-class I and class II molecules (48, 49). Finally, autophagy, which has a 
prominent role in cellular homeostasis and bacterial sequestration into vacuolar organelles, 
is involved in Ag presentation and cross-priming of T cells in response to intracellular 
pathogens, including Mtb (126, 127). 
It has been demonstrated that several pathways are used in order to activate CD8+ T cells by 
phagosomal Ags, and, very recently, MHC-class Ib-restricted CD8+ T cells have received 
attention, including a role for HLA-E, which presents peptides from a wide range of 
mycobacterial Ags (54, 128). CD1-restricted CD8 T cells recognize lipids such as mycolic 
acids and lipoarabinomannan from the bacterial cell wall (54) and lung MAIT recognize 
Mtb Ags in the context of the non-classical MR1 molecule (129). 
Thus, CD8+ T cell immunity offers evidences of their clear synergy of action and 
complementarities in association with CD4+ T cell immunity, for the fact that CD8+ T cells 
display other direct effector functions such as the secretion of granules that contain cytotoxic 
molecules as perforin, granzymes, and granulysin. These molecules can lyse host cells, or 
can have a direct killing toward Mtb and other bacteria. Moreover, CD8+ T cells can induce 
apoptosis of infected target cells through molecules such as Fas or TNF-R family-related 
cell-death receptors. Finally, CD8+ T cells release, upon activation, cytokines such as IFN-γ, 
TNF-α, and in many cases also IL-2. These functions are also used by MHC-class Ib-
restricted CD8+ T cells, suggesting a role for classical as well as non-classical CD8+ T cells 
in TB protection. 
From the functional point of view, different studies conducted in mice and non-human 
models have delineated a role for Mtb-specific CD8+ T cells in the control of Mtb infection 
(122–124). In these studies, it has been demonstrated that IFN-γ and perforin released by 
Mtb-specific CD8+ T cells were necessary to induce protection in Mtb-infected mice (122, 
125). The role of these molecules has been efforted in humans’ studies that have reported the 
same conclusions (41, 130). 
Hence, other in vitro studies have indicated that perforin- and/or granulysin-containing Mtb-
specific CD8+ T cell lines were able to kill Mtb-infected macrophages or even free bacteria 
(45, 131, 132), other studies have found the complete absence of these molecules released 
by Mtb-specific CD8+ T cells from lung-associated tissues (133, 134). 
Though it is not still possible to attribute a role to polyfunctional T cells as marker of 
protective immunity or of disease activity, multi-, or polyfunctionality of CD8 T cells is 
referred to the simultaneous production of several cytokines (IFN-γ, IL-2, TNF-α) and/or the 
expression of multiple effector functions (perforin, granulysin, cytolysis, etc.). However, 
contrary to initial expectations, these cells do not appear to correlate with BCG-induced 
protection in infants (135) and adults (136). Moreover, they are also present in active TB, 
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although they may nevertheless be part of the protective host response attempting to limit 
infection rather than contributing to active disease. 
Previously, we have correlated the frequency of Mtb-Ag85A-specific CD8+ T cells with the 
efficacy of anti-mycobacterial therapy in children. In particular, we found that Ag85A 
epitope-specific CD8+ T cells in children with active disease were able to produce low levels 
of IFN-γ and perforin, which recovered after successful therapy (137). In a later study, the 
analysis of the ex vivo frequencies, cytokine production, and memory phenotype of 
circulating CD8 T cells specific for different non-amers of Mtb proteins was performed in 
adult HLA-A*0201 different cohorts (107). 
We found a lower percentage of circulating tetramer specific CD8 T cells in TB patients 
before therapy respect to LTBI subjects, but values increased after 4 months of anti-
mycobacterial therapy to those found in subjects with LTBI. In this study, we also found 
high percentages of IL-2+/IFN-γ+ and single IFN-γ+ in subjects with LTBI, and a reduction 
of IL-2+/IFN-γ+ population in TB patients, suggesting a restricted functional profile of Mtb-
specific CD8 Tcells during active disease (107). 
Many studies have focused on the response to different Mtb Ags expressed in the early 
phase of infection such as ESAT6, CFP-10, and Ag85B proteins but further studies should 
also incorporate those Ags expressed at different phases of infection (60). 
Another study, using defined cohorts of individuals with smear-positive and smear-negative 
TB and LTBI subjects, evaluated Mtb-specific responses in correlation to mycobacterial 
load (113). The authors found, in individuals with high mycobacterial load smear-positive 
TB, a decrease of polyfunctional and IL-2-producing cells, and an increase of TNF-α+ Mtb-
specific-CD4 T cells and CD8 T cells, both of which had an impaired proliferative capacity 
(60). These patients were followed during the anti-mycobacterial therapy and it was shown 
that the percentage of triple positive CD8 T cells (producing IFN-γ, IL-2, and TNF-α) 
increased over time in 7 out of 13 patients and this increase was paralleled by decrease of 
the frequency of IFN-γ+ T cells, providing another evidence that the cytokine production 
capacity of Mtb-specific CD8 T cells is associated with mycobacterial load. 
In children or immunocompromised individuals, where it is very difficult to distinguish Mtb 
infection from disease, and in people that are at high risk to develop active disease, the 
increase of polyfuntional CD8 T cells and the reduction of single IFN-γ or TNF-α producing 
cells may be used to correlate these CD8 T cell subsets with TB disease progression, 
highlighting a new possible role as indicator of successful response to treatment. 
Mtb DosR-regulon encoded Ags (138) expressed by Mtb during in vitro conditions, 
represent rational targets for TB vaccination because they mimic intracellular infection. It 
has been shown that LTBI individuals are able to recognize Mtb DosR-regulon encoded Ags 
belonging to different ethnically and geographically distinct populations (60, 131, 138, 139). 
Moreover, Mtb DosR Ag-specific-CD4+ and -CD8+ polyfunctional T cells were found in 
LTBI subjects. In detail, a hierarchy of response, in terms of the ability of Ag-specific CD8 
T cells to produce one or more cytokines, was found. The highest response was observed 
among single cytokine producing CD4+ and CD8+ T cell subsets, followed by double 
producing CD4+ and particularly CD8+ T cells. In particular, the most frequent multiple-
cytokine producing T cells were IFN-γ+TNF-α+ CD8+ T cells. These cells were effector 
memory (CCR7− and CD45RA−) or terminally differentiated effector memory (CCR7− and 
CD45RA+) T cells, both phenotypes associated with the protective role of CD8+ T cells in 
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Mtb infection (60, 131, 140). Another important observation was the number of epitopes 
identified, in accordance with their immunogenicity and recognition by a wide variety of 
HLA backgrounds (141, 142). 
Therefore, the role of Mtb DosR-regulon encoded peptide Ag-specific single and double 
functional CD4+ and CD8+ T cell responses in LTBI, significantly improves the 
understanding of the immune response to Mtb phase-dependent Ags in the control of 
infection, and suggests a possible role for using Mtb DosR-Ag and/or peptide based 
diagnostic tests or vaccination approaches to TB. 
Several studies have tried to correlate the frequency, the phenotype, and the effector 
functions of CD8 T cells in patients with disease and subjects with latent infection. Here, we 
report other additional recent studies aimed at identify biological indicators useful to 
discriminate between patients with active disease, subjects with latent infection and patients 
that recovery after successful therapy. 
Niendak et al. have observed that specific CD8+ T cell response decreased by 58.4% at 
24 weeks, with the majority of the decrease (38.7%) noted at 8 weeks in subjects receiving 
successful anti-TB treatment (143); decrease of the CD8+ T cell response was relatively 
unaffected by malnutrition, supporting the hypothesis that the frequency of Mtb-specific 
CD8+ T cells declines with anti-tuberculosis therapy potentially as consequence of 
decreasing intracellular mycobacterial Ags, and may prove to be a surrogate marker of 
response to therapy (54, 144). The authors postulate that each individual has a CD8 “set 
point,” which reflects the complex interplay of antigenic exposure, in conjunction with host 
factors such as the HLA background. Nonetheless, these findings are concordant with the 
observation that removal of Ag results in decreasing T cell frequencies, and help to explain 
the observed reduction in CD8+ T cell frequency following anti-tuberculosis therapy. 
Another recent study of Harari et al. (112) highlighted phenotypic and functional properties 
of Mtb-specific CD8 T cell responses in 326 TB patients and LTBI subjects in order to 
correlate their presence with different clinical form of Mtb infection (94). Authors found a 
higher frequency of Mtb-specific CD8 T cell responses in TB patients, which was correlated 
with the presence of higher Ag load (94, 112). These results were confirmed by two 
different studies, the first performed in children with active disease, where Mtb-specific 
CD8 T cells were detected in active TB disease but not in healthy children recently exposed 
to Mtb (112), and the second that demonstrated the presence of higher number of 
granulomas in TB patients as compared with those in LTBI subjects (94). Moreover, major 
phenotypic and functional differences were observed between TB and LTBI subjects, as 
Mtb-specific CD8+ T cells were mostly represented by terminally differentiated effector 
memory cells (TEMRA) in LTBI and of TEM cells in TB patients. These results also 
suggests that TEMRA and TEM cell subsets, are involved in the control of Mtb infection, as 
already demonstrated in chronic controlled and uncontrolled virus infection, respectively 
(94, 145). 
The authors did not find any statistically significant difference in the cytokines profile of 
Mtb-specific CD8+ T cell responses between LTBI subjects and TB patients, while they 
found that Mtb-specific CD8+ T cells were more polyfunctional (i.e., IFN-γ+TNF- α+IL-2+) 
in LTBI subjects, according to the role that these cells play in anti-viral immunity (94, 145). 
Instead, it was found that Mtb-specific CD8+ T cells have a higher frequency as single TNF-
α-producer cells in TB patients, as occurred for CD4+ T cells (145). Further analysis of the 
 28 
functional properties of these Mtb-specific CD8+ T cells, permitted to detect significant high 
levels of GrB and GrA, but low level of perforin, suggesting a mechanism of action of Mtb-
specific CD8+ T cells that is independent on the expression of perforin (94). 
Another intriguing aspect of that study was the finding of a higher prevalence of Mtb-
specific CD8+ T cell responses in pulmonary TB patients compared with extra-pulmonary 
TB patients and the higher magnitude of these responses in smear-positive versus smear-
negative pulmonary TB patients (94). Moreover, Mtb-specific CD8+ T cells from pulmonary 
TB patients were not able to proliferate compared to CD8 T cells from extra-pulmonary TB 
patients (94). These functional differences of the CD8 T cell responses, in term of cytokines 
release or proliferation, most likely depend on antigenic stimulation that occur at different 
anatomic sites, that could be correlated with high Ag burden (108, 146, 147), attributing to 
tropism of responding T cells (94). 
In conclusion, Mtb-specific CD8 T cell response, as defined by the qualitative and the 
quantitative aspects above cited, could have significance in understand how the immune 
system fails to control the progression of TB, or how the quality of the response could 
facilitate early diagnosis in order to reduce TB associated morbidity and mortality and to 
individuate subjects that are at high risk to develop active disease (60).  
 
Role of T Cells in TB-HIV Co-infection 
HIV infection has led to an increase in the incidence of TB, and TB-HIV co-infection has 
determined not easy decisions in both the diagnosis and treatment. The treatment of co-
infected patients requires anti-tuberculosis and antiretroviral drugs to be administered 
together. The therapeutic treatment leads to different results, according to patient 
compliance, drug toxic effects, and, finally to a syndrome that appears following the 
initiation of antiretroviral therapy (ART) named immune reconstitution inflammatory 
syndrome (IRIS). 
Several studies have provided to clarify the relationship that exists between HIV and Mtb 
pathogens and how they interact both in vitro and in vivo, highlighting how HIV infection 
could increase the risk of TB and how Mtb infection may accelerate the evolution of HIV 
infection. Flynn et al., very recently, have summarized the results obtained from different 
studies, discerning the several hypotheses on the role of the immune system in the co-
infection (148). 
It is well known that TB-HIV co-infection is destructive (149–151), but nowadays the 
mechanisms involved in the impairment of the immune system, guiding to the morbidity and 
mortality of co-infected subjects, remain to be elucidated (152). In countries with low rates 
of TB and, of course, with high-burden TB, the identification of LTBI within individuals co-
infected with HIV is important due to the high risk to develop active TB. One of the control 
strategy adopted by the WHO is the use of preventive therapy of LTBI with isoniazid (INH) 
treatment (153). HIV-infected individuals are at high risk to develop active TB for the 
progressive CD4 depletion in the first few years after infection, even if the number of 
peripheral CD4 T cells is still high at the beginning (154–156). Although, the ART could 
restore absolute CD4 T cell numbers, it does not reduce the risk of TB progression in HIV 
patients (157). Conversely, TB infection has a negative impact on clinical progression of 
HIV infection (158). 
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Studies of human disease have characterized functional defects in CD4 T cells in TB-HIV 
co-infection by the analysis of cytokine production (e.g., IFN-γ) by CD4 cells in response to 
Mtb Ags (159–162) and by the analysis of phenotype distribution of CD4 T cells in 
lymphoid tissue, peripheral blood, and at the sites of disease (159, 163, 164). The correlation 
of different phenotypes of Ag-specific-CD4 T cells, and their role on the protection or 
susceptibility to infection, has been clearly demonstrated by the emerging characterization of 
polyfunctional CD4 T cells in TB-HIV co-infection. In the peripheral blood of TB-HIV-
infected people, CD4 T cells are less able to secrete more than one cytokine when the viral 
load is high (165). Kalsdorf et al. have demonstrated that polyfunctional T cells specific for 
mycobacterial Ags are reduced in BAL from latent TB-HIV-infected subjects with no 
symptoms of active TB. The impairment of mycobacterial specific T cells could contribute 
to develop active TB, suggesting that HIV infection affects the frequency of Ag-specific 
polyfunctional T cells in the BAL of people with latent TB-HIV (160). Therefore, several 
studies have tried to correlate the presence of these cells in blood or in fluids recovered at 
the site of infection, highlighting how their presence can be reduced or increased, in term of 
absolute number. In fact, some authors have found a reduction of polyfunctional CD4 T cells 
in the peripheral blood of HIV-infected infants, in response to restimulation with BCG, 
compared with HIV-uninfected infants, or in BAL samples from HIV-infected subjects 
compared with HIV-uninfected healthy subjects, and finally, an increase in pericardial fluid 
of TB-HIV patients, with a terminally effector phenotype (163). Matthews et al. have found 
a lower proportions of Ag-specific polyfunctional T cells, with the less mature phenotype of 
CD4 T memory, at the site of disease of both HIV-infected and uninfected TB patients, 
supporting the hypothesis that their presence could correlate with Ag load and disease status, 
instead than with protection (163). Finally, understanding how the immune system 
contributes to TB-HIV co-infection could provide the basis for the discovery and 
development of new drugs and vaccines that can prevent or cure TB in co-infected people. 
At the moment, an early ART treatment still represents the gold standard in the control of 
TB-HIV co-infection. 
 
Concluding Remarks 
Tuberculosis research in the field of vaccine and diagnostic tests development suffers from 
lack of rigorous correlates of protection in order to better understand the basic mechanisms 
underlying pathophysiology. Therefore, the identification of biosignatures that predict risk 
of disease, but also vaccine efficacy would be important. 
Studies of human T cell responses, using different protocols of in vitro stimulation, have 
made possible to delineate some functional signatures indicative of the immunological status 
of each studied individual (60). 
From the above cited studies, it has clearly emerged that, for TB diagnosis it is necessary to 
investigate on several biomarkers. The different expression levels of several cytokines, 
evaluated ex vivo in cells obtained from blood samples, comparing uninfected subjects, 
LTBI individuals, and patients with active disease, led to not unique results. This issue, 
therefore, requires further investigation by different analytical platforms. In particular, we 
believe that TB biomarkers research may continue to generate signatures with clinical 
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applicability and additionally provides novel hypotheses related to disease pathophysiology 
(166). 
Finally, the identification of such functional T cell signatures could help to better make 
diagnosis of different stages of TB, including also the cases of risk of reactivation and/or 
progression to active disease such as occurs in HIV patients (166). 
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T-cell mediated immune responses play a fundamental role in fighting against Mtb (167, 
168). Traditionally, this response is mediated by Th1-type CD4 T cells secreting IFN-γ (168, 
169), but it has become clear that CD8 T cells also contributeto protective immunity against 
Mtb (170) by the releaseof Th1-type cytokines and cytotoxic and microbicidal molecules 
that promote killing of Mtb infected macrophages and restrict the growth of intracellular 
bacilli (168). In humans, Mtb reactive CD8 T cells recognize peptides associated to classical 
HLA-A, HLA-B, and HLA-C class I (class Ia) molecules, glycolipids associated to group 1 
CD1 molecules (171, 172), and mycobacterial Ag associated to MHC class I related 
molecule (MR1) (173). However, there is little information on the role that these cells play 
during infection. In mice, the MHC class Ib molecule H2-M3 binds formylated peptides 
derived from Mtb and induces H2-M3-restricted CD8 T cells (174, 175) that are protective 
against Mtb infection (176). 
In humans, CD8 T cells restricted by class Ib molecules comprise the very large majority of 
the overall Mtb specific CD8 T cell response (177) and CD8 T cells recognizing Mtb Ags in 
the context of the class Ib molecule HLA-E have been isolated from subjects with latent Mtb 
infection (178, 179). However, the functions of this HLA-E-restricted population, as well as 
its contribution to the host response to Mtb during infection and disease, remain unknown. 
HLA-E is the least polymorphic of all the HLA molecules (180) with only two alleles in the 
Caucasian population, which differ at one aa position located outside the peptide binding 
groove (181). Physiologically, HLA-E binds nonamer peptides derived from the signal 
sequence of other HLA class I molecules (182, 183), and the HLA-E/peptide complex in 
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turn binds to CD94/NKG2A (inhibitory) and CD94/NKG2C (activating) NK receptors (183-
185). However, HLA-E also binds peptides derived from self-Ags (186, 187), tumors (188), 
and pathogenic microorganisms (179, 189-192), including Mtb (177, 179), and presents 
them to CD8 T cells. The lack of allelic variation in the peptide-binding groove maybe 
advantageous to design peptide-based vaccines against TB. In fact, while the polymorphism 
of MHC class Ia molecules is an obstacle for clinical application of these peptide based 
vaccination strategies, vaccines based on peptides presented by HLA-E are suitable for the 
global heterogenic population. In addition to its limited polymorphism, HLA-E offers 
another potential advantage in relation to Mtb infection. As opposed to HLA-A and HLA-B 
molecules, HLA-E is resistant to HIV-nef-mediated downregulation (193, 194). This is 
particularly relevant in view of the high prevalence of HIV/Mtb co-infection in countries 
such as South Africa where approximately 70% of TB patients are also HIV infected (195). 
Thus, while HIV might affect recognition of Mtb coinfected macrophages (196) by HLA 
class Ia molecules, HLA-E-dependent Ag presentation and target-cell recognition are likely 
to be less or not affected at all by HIV co-infection. Therefore, targeting Mtb specific HLA-
E-restricted responses by vaccination or immunotherapy might be a novel and advantageous 
approach to combat TB. 
In this article we have studied the epitope specificity, functional attributes, and ex vivo 
frequencies of HLA-E-restricted CD8 T cells specific for Mtb peptides in patients with 
active TB. We show here that HLA-E-restricted CD8 T cells recognize Mtb peptides in a 
CD3/TCR αβ mediated and CD8-dependent manner. Moreover, we provide evidence that 
during active TB disease, these cells produce type 2 (Tc2) cytokines, help B cells for Ab 
production, and have very poor TRAIL-mediated cytolytic activity and microbicidal 
potential. Finally, using HLA-E/Mtb peptide tetramers we show that the frequency of such 
tetramer specific CD8 T cells declines after successful chemotherapy, indicating that this 
novel human T-cell population participates inimmune response in TB. 
 
Results:  
Identification of predicted HLA-E-binding Mtb peptides 
A recent study using a combination of several bioinformatic methods has led to the 
identification of 69 potential HLA-E-binding peptidesfrom the total Mtb H37Rv genome 
(179). Despite differences in their binding affinities to recombinant human HLA-E, 79% 
peptides were recognized by at least one healthy purified protein derivative (PPD) 
responder, in a CD8 T cell proliferation assay (179). Thus, and as found for other HLA class 
I molecules as well (197), actual affinities determined in this biochemical cell-free binding 
assay do not fully correlate with epitope recognition by CD8 T cells. Therefore 18 peptides 
(Supporting Information Table 1) were chosen to represent groups of six peptides each 
that display high, intermediate, and low binding affinity to HLA-E molecule in a cell-free 
assay, and these peptides were screened for their capability to induce HLA-E cell surface 
expression and to elicit peptide-specific response of CD8 T cells from at least 30% of 
patients with active TB disease.  
To test the capacity of the Mtb peptides to bind HLA-E, we performed a stabilization assay 
(183, 184, 198) in which TAP deficient RMA-S (TAP2 mutant Rauscher Murine Leukemia 
virus induced T cell lymphoma) cells transfected with HLA-E (RMAS/HLA-E) were 
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cultured in the presence or absence of peptide at 37°C overnight and cell-surface expression 
of HLA-E analyzed by flow cytometry. In the absence of peptide, there was no evidence of 
HLA-E expression (Supporting Information Figure 1A).  
The canonical VMAPRTLIL sequence (used as a positive control) identical to that present in 
the leader sequence of most HLA-C alleles (199) was able to stabilize HLA-E expression. 
Interestingly, culture with Mtb peptide 44 resulted in the highest levels of HLA-E 
expression. Peptide 34 also stabilized HLA-E cell surface expression although not to the 
extent of peptide 44. Co-culture with peptides 62 and 68 resulted in somewhat lower, but 
significant surface levels of HLA-E expression compared to peptide 44, while peptide 55 
stabilized only poorly HLA-E molecules on RMA-S/HLA-E cells. 
All other tested Mtb peptides failed to stabilize HLA molecules on transfected RMA-S cells. 
Together the data demonstrated that 5 of the 18 tested Mtb peptides (i.e. peptides 34, 44, 55, 
62, and 68) were able to stabilize surface expression of HLA-E, albeit to varying degrees. In 
parallel with the analysis of HLA-E surface expression, the 18 Mtb peptides were tested for 
their capability to induce proliferative responses of CD8 T cells from ten patients with active 
TB. Peptide-induced CD8 T cell responses were scored positive when exceeding 10% 
proliferation in the absence of peptide (see Materials and Methods and (179), in at least 30% 
of the tested TB patients. According to these criteria, a total of 4 of the 18 tested peptides 
(i.e. peptides 34, 55, 62, and 68) were found to elicit a CD8 T cell response (Supporting 
Information Fig. 1B).  
When HLA-E surface expression and CD8 T cell response results were compared, peptides 
34, 62, and 68 were found capable of stabilizing HLA-E surface expression and eliciting a 
CD8 T cell response; peptide 44 caused the highest HLA-E surface expression but a very 
low CD8 T cell response and conversely, peptide 55 induced relatively low HLA-E surface 
expression but significant CD8 T cell response. Therefore, because HLA-E cell surface 
stabilization did not fully correlate with the CD8 T cell response, in subsequent experiments 
we decided to use the five peptides that gave a positive result in either assay. 
 
HLA-E/Mtb peptide complexes are not recognized by CD94/NKG2 
receptors 
The C-type lectin receptors CD94/NKG2A and CD94/NKG2C specifically interact with 
HLA-E, resulting either in inhibition or activation of NK-cell function (183-185). Therefore 
we tested theability of Mtb peptides to affect target-cell lysis by NK cell clones expressing 
either CD94/NKG2A or CD94/NKG2C. 
In order to address whether complexes of HLA-E and Mtb peptides inhibit lysis mediated by 
CD94/NKG2A+ NK cells, the HLA class I negative K562 cells were transfected with HLA-
E (K562/HLA-E) and were incubated overnight at 37°C with either Mtb peptides or the 
VMAPRTLIL peptide (used as control) and tested as targets in a 51Cr release assay (Figure 
H1A). As expected, K562/HLA-E cells were efficiently killed by CD94/NKG2A+ NK-cell 
clones (e.g. 26.3 and 7.1 clones) and incubation of target cells with the VMAPRTLIL 
reference peptide was able to protect them from killing (Figure H1A). Pre-incubation of NK 
cells with anti-CD94 mAb reversed inhibition of cytolysis, demonstrating recognition of 
HLA-E/VMAPRTLIL complexes by the inhibitory CD94/NKG2A receptor (Figure H1A). 
In contrast, all tested Mtb peptides failed to protect K562/HLA-E cells from killing by 
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CD94/NKG2A+ NK-cell clones and cytotoxicity was not (or was only minimally) altered by 
the presence of anti-CD94 mAb (Figure H1A). 
 
 
 
Figure H1: Mtb derived peptides are not recognized by NKG2A+ by NKG2C+ NK-cell clones.(A) 51Cr-
labeled K562/HLA-E cells were incubated either alone (no peptide) or in the presence of the VMAPRTLIL 
peptide (Control peptide) or the indicated Mtb peptides and were tested for susceptibility to lysis by NKG2A+ 
NK-cell clones (26.3 and 7.1) at different E:T ratios in the absence (black) or presence (white) of anti-CD94 
mAb Y9 (IgM). (B) 51Cr-labeled RMA-S/HLA-E cells were incubated as in (A) and were tested for 
susceptibility to lysis by NKG2C+ NK-cell clones (41.3 and 21.6) at different E:T ratios in the absence (black) 
or presence (white) of anti-CD94 mAb Y9 (IgM). (A and B) Data are from one experiment representative of 
five independent experiments, each performed in duplicate. 
 
 
We then investigated whether HLA-E molecules loaded with Mtb peptides are recognized 
by NK-cell clones expressing a functional activatory CD94/NKG2C receptor. To this end, 
RMA-S/HLA-E cells incubated with either Mtb peptides or the VMAPRTLFL reference 
peptide (used as control) were tested as targets in a 51Cr release assay with the 
CD94/NKG2C+ NK cell clones 41.3 and 21.6 as effectors. VMAPRTLFL-loaded 
RMAS/HLA-E cells were killed more efficiently than control target cells (i.e. unpulsed 
RMA-S/HLA-E) and lysis of VMAPRTLFL-pulsed RMA-S/HLA-E cells was inhibited on 
mAb-mediated masking of CD94 (Figure H1B). In contrast, incubation of RMA-S/HLA-E 
cells with the Mtb peptides had no impact on target-cell recognition by CD94/NKG2C+ NK-
cell clones and the presence of anti-CD94 mAb did not alter target-cell lysis. Taken together, 
these results indicate that complexes of HLA-E and Mtb peptides do not engage inhibitory 
or activatoryCD94/NKG2 receptors. 
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Recognition of HLA-E/Mtb peptides requires the TCR αβ and is CD8 
dependent 
To further investigate the Ag-recognition requirements of the HLA-E-binding Mtb peptide-
responding T cells in more detail, we examined responses in three TB patients against five 
peptides using peptide-specific polyclonal CD8 T cell lines generated by peptide stimulation 
of PBMCs. Donors were selected on the grounds that (i) there was peptide-dependent CD8 T 
cell-proliferative response in that specific donor and (ii) sufficient PBMCs were available. 
Phenotype characteristics of the lines are summarized in Supporting Information Table 2 
and representative data with the E#68-1 cell line are shown in Supporting Information 
Figure 2.  
T-cell lines displayed a CD3+ CD8+ TCRαβ + phenotype and did not express either CD56 or 
CD16. CD94 was expressed by 8 of the 15 lines on an average of 22% of the cells. 
Similarly, the activatory NKG2C receptor was expressed by less than 15% of the cells in 
only three lines, and the inhibitory NKG2A receptor was expressed by 2 of the 15 tested cell 
lines, on less than 20% of their cells. Three lines expressed granzyme B and TRAIL on the 
vast majority of cells, but none expressed perforin and granulysin. All the tested CD8 T cell 
lines exhibited fine Ag specificity and strict HLA-E dependence, as demonstrated by their 
capability to produce TNF-α only when stimulated by K562/HLA-E cells loaded with the 
specific peptide. Figure H2A shows primary data obtained with five representative T cell 
lines. In no case TNF-α productionwas detected by stimulation of CD8 T cell lines with 
peptide pulsed K562 cells (data not shown). To assess the contribution of the TCR or NK 
receptors andHLA-E interaction to target-cell recognition, we performed mAbblocking 
experiments, in which peptide-loaded K562/HLA-E cellswere used to stimulate TNF-α 
production by CD8 T cell lines. As shown in Figure H2B, significant inhibition of TNF-α 
production was observed in the presence of blocking mAbs to CD3, TCR αβ,CD8, pan-HLA 
class I, or HLA-E molecules. Blocking mAbs specific for NKG2D, NKG2C, CD94, or 
HLA-A/B/C molecules had no inhibitory effect on this process, while capable to inhibit 
killing of target cells by NK or HLA-A*0201-restricted CD8 T cell clones (Supporting 
Information Figure 3). 
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Figure H2. Peptide specificity and recognition requirements of Mtb specific HLA-E-restricted CD8 T 
cell lines.(A) CD8 T cell lines (5x104) were cultured for 24 h with an equal number of irradiated K562/HLA-E 
cells pulsed or unpulsed with peptides, and TNF-α production assessed by ELISA. (B) CD8 T cells were 
stimulates as in (A) but in the presence of the indicated blocking mAbs. After 24 h, the supernatants were 
collected and TNF-α levels were assessed by ELISA. Data are shown as mean ±SD (n=3) and are pooled from 
two independent experiments, each performed in triplicate. *p< 0.001 when compared to control, as calculated 
by the Mann–Whitney U test. 
 
 
Together, these data unveil the requirement for TCR αβ mediated and CD8-dependent 
recognition of HLA-E-binding Mtb peptides. 
 
Functional properties of HLA-E-restricted and Mtb specific CD8 T cells 
To assess the cytokine profile of HLA-E-restricted and Mtb specific CD8 T cells, we 
stimulated T cell lines with specific peptides and tested cytokine production by ELISA in 
24-h supernatants. All 15 CD8 T cell lines produced TNF-α and 2 lines also produced low 
yet detectable levels of IL-2 (Figure H3A). Additionally, 9 of the 15 tested cell lines 
produced significantly IL-4 and IL-13, either alone or in combination with, IL-5, IL-10, 
and/or TGF-β, while we failed to detect production of IFN-γ, IL-17, and IL-22. Cytokine 
production was strictly peptide specific as no significant cytokine production was detected 
with T cell lines stimulated by peptides different than those used to generate the line. Figure 
H3B shows representative specificity results with two different CD8 T cell lines, E#34-1 
and E#68-3. Even if the generation of HLA-E-restricted CD8 T cell lines was carried out 
under neutral culture conditions (i.e. with IL-2 and in the absence of polarizing cytokines), 
we cannot exclud that their cytokine pattern may be biased by prolonged in vitro 
stimulation. Therefore, we decided to define the cytokine produced by CD8 T cells directly 
ex vivo upon stimulation of PBMCs from seven patients with active TB disease with Mtb 
peptides. Intracellular cytokine staining confirmed the dominant IL-4 and IL-13 cytokine 
production by the CD8+ T cells and the lack of IFN-γ secretion. Primary data from seven TB 
patients (with PBMCs) stimulated with peptide 68 are shown in Supporting Information 
Figure 4.  
Thus, and differently from CD8 T cells recognizing Mtb peptides in the context of HLA-
class Ia molecules (197, 200–203), CD8 T cells recognizing Mtb peptides presented by 
HLA-E have an unorthodox Tc2-like, multifunctional phenotype. Therefore, we looked into 
whether these cells support B cells to secrete Ig. To that end, CD8 T cell lines were cultured 
in the presence of sorted tonsillar CD19+ B cells and Ab production assessed by ELISA. B 
cells produced comparable low amounts of IgG and IgM when cultured for 10 days without 
CD8 T cell lines. In contrast, coculture of B cells with 9 of the 15 HLA-E-restricted CD8 T 
cell lines resulted in a significant increase in the production of IgG and IgM. As a control, 
coculture of tonsillar B cells with sorted CD8+ T cells isolated from the PBMCs of healthy 
donors did not increase significantly Ab production. Figure H3C shows representative 
experiments with three different HLA-E-restricted CD8 T cell lines. These data indicate that 
CD8 T cells recognizing Mtb peptides presented by HLA-E supply B cells with thesignals 
required for Ig production. 
 
 38 
 
 
Figure H3. Cytokine production and induction of IgG synthesis by Mtb specific HLA-E-restricted CD8 
Tcell lines.(A and B) CD8 T cell lines were stimulated with specific peptide as described above for 24 h, the 
supernatants were collected and cytokine levels were assessed by ELISA. Data are mean of three independent 
experiments, each performed in triplicate (SD < 10% of the means). (B) Data shown are from two 
representative CD8 T cell lines. (C) Tonsillar B cells were cultured for 10 days either alone (black-filled 
columns) or in the presence of HLA-E-restricted CD8 T cell lines (gray-filled columns) or normal CD8 T cells 
sorted from PBMCs (white columns). IgG and IgM concentrations in the culture supernatants were determined 
by ELISA. A representative example with three different CD8 Tcell lines is shown. Data are shown as mean 
±SD (n = 3) and are representative of four independent experiments *p < 0.001 when compared to B cells 
cultured alone, as calculated by the Mann–Whitney U test. 
 
With regard to their potential ability to develop cytotoxic responses, only 3 of the 15 tested 
CD8 T cell lines were equipped with specific lytic activity, E#44-1, E#55-2, and E#68-1 
(Figure H4A), as shown by their ability to kill K562/HLA-E cells pulsed with the specific 
peptide (Figure H4B). Most notably, the three cytotoxic CD8 T cell lines were also able to 
kill K562/HLA-E or human monocytic THP-1 target-cell lines infected with virulent Mtb 
(Figure H4C), indicating that the HLA-E-restricted peptides they recognize are generated 
during natural infection. However, HLA-E-restricted CD8 T cell lines only minimally 
reduced the viability of intracellular Mtb (Figure H4D) in K562 and THP-1 targe lines. As a 
control, an HLA-A*0201-restricted CD8 T cell clone specific for Mtb Ag 16-kDa 120–128 
was fully able to reduce the viability of intracellular Mtb. 
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Figure H4. Cytotoxic activity of Mtb specific HLA-E-restricted CD8 T cell lines.(A) Cytotoxic activity of 
15 different HLA-E/Mtb peptide specific CD8 T cell lines toward peptide-pulsed or unpulsed K562/HLA-E 
target cells. (B) Peptide specificity in the killing activity of three different CD8 T cell lines toward K562/HLA-
E target-cell lines pulsed with the specific or irrelevant peptides. (C, D) Three different HLA-E/Mtb peptide 
specific CD8 T cell lines were coincubated with uninfected or Mtb H37Rv infected K562, K562/HLA-E, and 
THP-1 cell line target cells. Cytotoxic activity toward targets was assessed after 6-h coculture, while Mtb 
CFUs were estimated after 20-h coculture. The human HLA-A*0201-restricted CD8 T cell clone specific for 
Mtb Ag 16-kDa120-128 (218) was used as a positive control. (A–D) Bars represent mean ±SD (n = 3) and data 
are from one experiment representative of five independent experiments. (A) *p< 0.005 and **p < 0.01 when 
compared to unpulsed K562/HLA-E target cells, as calculated by the Mann–Whitney U test. (B) *p< 0.001 
when compared to unpulsed target cells. (C) *p< 0.002 when compared to uninfected K562 and THP-1 target 
cells, as calculated by the Mann–Whitney U test. (D) *p< 0.005 and **p < 0.01 when compared to control, as 
calculated by the Mann–Whitney U test. 
 
To further elucidate the mechanisms responsible for killing of CD8 T cells recognizing Mtb 
peptides in the context of HLA-E, we individually inhibited the granule exocytosis-, 
TRAIL-, TNF-α-, and FasL-mediated (FasL is Fas ligand) pathways. In agreement with flow 
cytometry data (Supporting InformationTable 2), treatment of CD8 T cells with 
concanamycin A (CMA), an inhibitor of vacuolar type H+-ATPase that blocks perforin 
based cytotoxic activity, had no effect on killing of peptide-treated K562/HLA-E-cell targets 
(Supporting Information Figure 5), thus excluding involvement of the perforin pathway.  
Addition of mAbs against TRAIL-R1 and TRAIL-R2 caused 82–86% inhibition of target-
cell killing, indicating that TRAIL played a major role in the killing activity of HLA-E-
restricted CD8 T cell lines. Finally, mAbs to FasL and TNF-α failed to significantly inhibit 
the cytotoxicity of all three tested HLA-E-restricted CD8 T cell lines. 
 
Validation of HLA-E-restricted and Mtb-specific CD8 T cells using 
tetramers 
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Using HLA-E/peptide tetramers for four HLA-E-binding peptides, direct ex vivo recognition 
by TB patients CD8 T cells was demonstrated for all four Mtb epitopes (Figure H5A and 
B). In all tested individuals, specificity of tetramer staining was confirmed by the absence of 
staining among PBMCs from ten normal, uninfected donors using the same Mtb tetramers 
(Figure H5A). 
 
 
 
Figure H5. Ex vivo analysis of the frequencies of HLA-E/Mtb peptide tetramer+ CD8 T cells.(A) Dot plot 
analysis of HLA-E/peptide tetramer+ CD8+ T cell populations of one representative healthy tuberculin-negative 
subject, LTBI subject, and TB patient with active or cured TB disease, with or without HIV co-infection. 
Shown in the upper left of each FACS plot are the percentages of tetramer+ CD8+ T cells, for all four tested 
Mtb peptide/HLA-E tetramers. Data shown are representative of three independent experiments. (B) 
Cumulative data on the frequencies of the tetramer-specific CD8 T cells in peripheral blood of 11 LTBI 
subjects (black columns) and 24 TB patients with active (gray columns) or cured (white columns) TB disease. 
Data are shown as mean ±SD (n = 3) and are representative of three independent experiments. *p< 0.01 and 
**p < 0.02 when compared to patients with active TB disease, as calculated by the Mann–Whitney U test. 
 
Although there was considerable variability in the proportions of CD8 T cells that bound to 
single tetramers, the ex vivo frequencyof tetramer-specific CD8 T cells was higher in TB 
patients than in latent tuberculosis infection (LTBI) subjects and this difference attained 
statistical significance with all epitopes. Significant differences in frequencies of epitope-
specific CD8 T cells were observed in TB patients before and after chemotherapy: in all 
instances mean frequencies of epitope-specific CD8 T cells significantly decreased after 
therapy and differences attained statistical significance with most of the studied epitopes (i.e. 
peptides 44, 55,and 62). Finally, and most notably, the highest mean frequency of tetramer-
specific CD8 T cells was found in three TB patients who were coinfected by HIV, which 
declined after antituberculous therapy as well. Figure H5A shows FACS analysis of the 
CD8+ tetramer+ T cells of one individual from any tested group and Figure H5B shows 
cumulative data from 24 patients with active TB disease before and after therapy, and 11 
LTBI individuals.  
As five TB patients were typed as HLA-A*0201+ and we had available HLA-A*0201/Mtb 
peptide tetramers, we followed up the CD8 T cell response to HLA-A*0201- and HLA-E 
restricted epitopes in the same patients during therapy. As shown in Figure H6, the 
frequencies of HLA-E-epitope-restricted CD8 T cells significantly decreased after 6-month 
therapy, while mean frequencies of HLA-A*0201-restricted, epitope-specific (ESAT-
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6,Rv1490, Ag85, and 16-kDa Ags) CD8 T cells increased after therapy. Thus, the opposite 
trend of HLA-E- and HLA-A*0201-restricted responses strongly suggests these two CD8 T 
cell populations may play different roles during Mtb infection and disease. 
 
 
 
Figure H6. Comparison of the frequencies of HLA-A*0201/Mtbpeptide and HLA-E/Mtbpeptide 
tetramer+ CD8 T cells during antimycobacterial therapy. Frequency of (A) HLA-E/Mtb and (B) HLA-
A*0201/Mtb tetramer+ CD8+ T cells in PBMCs of five HLA-A*0201-positive TB patients (patients) before 
(TB0) chemotherapy and 4 (TB4) and 6 (TB6) months after chemotherapy. Data shown are representative of 
three independent experiments. 
 
Discussion 
Within recent years, it has become clear that HLA-E can present peptides from several 
bacteria and viruses to CD8+ T cells in a manner comparable to peptides presented by 
classical MHC class I molecules (180, 190, 204–208). Indeed, HLA-E-restricted CD8+ T cell 
recognition of peptides from pathogens may be an important mechanism of immune 
regulation during infections, as was first demonstrated for Mtb (178, 179). HLA-E is 
enriched in the Mtb phagosome compared to regular HLA class I molecules (209), 
suggesting that HLA-E may have unique functions in presenting phagosomal Ags. Because 
Mtb resides in immature phagosome, the probability that some peptides derived from Mtb 
could be presented to CD8 T cells during active infection in association with HLA-E 
molecules is intriguing. Accordingly, careful examination of HLA-E-restricted CD8+ T cell 
responses to peptides from Mtb found such responses to a number of these peptides (179). 
Therefore in our study, we were interested in examining whether TB patients had a 
detectable CD8+ T cell response to peptides derived from Mtb, which have been shown 
capable to bind to HLA-E. 
In this article, using a selected pool of Mtb peptides capable to stabilize the HLA-E 
molecule on the surface of transfected cells and to induce proliferation of CD8 T cells in 
PBMCs from at least 30% TB patients, we provide direct evidence that during active TB 
HLA-E-restricted CD8 T cells can recognize such Mtb peptides, thus representing an 
additional type of effector cells playing a role in immune response to active infection with 
Mtb. Usually, HLA-E/peptide complexes may serve as a ligand for CD94/NKG2A or C, 
which are NK-cell-inhibitory and NK-cell activating receptors, respectively (183, 184). 
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CD94/NKG2A appears to bind ligand with higher affinity, which has led to the notion that 
HLA-E/peptide complexes may protect target cells from NK-cell-mediated killing (210, 
211). Conversely, engagement of CD94/NKG2C promotes NK-cell killing (210, 211). In 
theory, presentation of the Mtb derived peptides by HLA-E molecule may have similar 
consequences. However, and in contrast to the HLA-E/self-peptide complexes, we did not 
find recognition of HLAE/Mtb peptide complexes by NK-cell clones selectively expressing 
inhibitory (NKG2A) or activatory (NKG2C) receptors. Thus, we propose that HLA-E/Mtb 
peptide complexes may have very low or even impaired affinity for CD94/NKG2A or C 
receptors. Moreover, using T cell lines generated from PBMCs of TB patients by long-term 
peptide stimulation in vitro, we demonstrate that CD8+ T cells recognize HLA-E/Mtbpeptide 
complexes. Importantly, HLA-E/Mtb peptide complexes are recognized differently from 
HLA-E/self-peptides: whereas the latter are predominantly recognized by CD8-negativecells 
(subset of NK cells) in a CD94-dependent manner, HLA-E/Mtb peptides are specifically 
recognized by CD8+ T cells in a CD3/TCR αβ mediated and CD8-dependent manner. 
Finally, HLA-E/Mtb peptide tetramers did not bind to CD8-negative cells, although this 
subset is expected to containan NK-cell subset expressing CD94/NKG2. Altogether, the 
above reported results strongly indicate that HLA-E-restricted CD8T cells recognize Mtb 
peptides differently than NK cells but in a similar manner as HLA-class I-restricted CD8 T 
cells. 
Human CD8+ Tcell lines derived from TB patients efficiently recognize HLA-E-binding 
Mtb peptides, resulting in cell proliferation, but the responding cells had very poor cytotoxic 
activity to HLA-E-expressing cells (K562 and THP-1). This was initially suspected by the 
lack of expression of perforin and granulysin, and confirmed by the finding that only 3 of 
the 15 tested HLA-E-restricted Mtb specific CD8 T cell lines lysed these target cells. 
Nonetheless, killing of targets occurred in a peptide-specific and HLA-E-dependent fashion, 
strongly suggesting peptide/HLA-E cognate recognition via the TCR. Moreover, these 
epitopes are also likely recognized during natural infection, since live Mtbinfected 
K562/HLA-E and THP-1 cell lines were lysed by HLA-E/peptide-specific effector CD8 T 
cells. However, despite their capability to kill peptide-pulsed and Mtb infected target cells, 
all three HLA-E-restricted CD8 T cell lines caused only minimal, if any inhibition of Mtb 
outgrowth from these infected human cell lines, indicating that they are equipped with 
cytolytic potential but lack microbicidal activities. The latter finding could indicate that 
HLA-E-restricted Mtb peptide specific CD8 T cells during active TB have an impaired 
ability to inhibit Mtb outgrowth, since in another study (submitted) we find that T cell 
clones from latently infected individuals were able to inhibit Mtb outgrowth from infected 
primary human macrophages. Alternatively, experimental differences (e.g. the use of cell 
lines here versus primarycells in our other study) might account for this seeming difference. 
In any case, the lack of correlation between target-cell apoptosis and antimicrobial activity 
by Mtb specific CD8 T cells is not surprising and was first reported by Modlin and co-
workers (171). 
In addition to their poor cytolytic capacity, HLA-E/peptide reactiveCD8 T cell lines from 
TB patients also had an unusual Tc2-type pattern of cytokine production: they secreted 
TNF-α and two lines also produced low, yet detectable, levels of IL-2. However, and 
surprisingly, 9 of the 15 tested cell lines secreted IL-4 and IL-13, either alone or in 
combination with IL-5, IL-10, and/or TGF-β, while very low or no production of IFN-γ, IL-
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17, and IL-22 was detected. The cytokine production profile of HLA-E-restricted CD8 Tcell 
lines was confirmed by intracellular staining of freshly isolated CD8 T cells stimulated with 
Mtb peptides. Thus, HLA-E/Mtb peptide specific CD8 T cells more closely resemble Tc2 T 
cells and accordingly they are capable to provide help to B lymphocytes for Ab production. 
Moreover, the finding that some CD8 T cell lines also secrete TGF-β suggests that a fraction 
of these cells might play regulatory activities, as shown by previous studies in autoimmune 
disease models (212) and response to microorganisms (213), including TB (179). Overall, 
data reported here differ from previously described HLA-E-restricted, TB-specific CD8 T 
cells that produce IFN-γ and are cytolytic (178, 179). However, we would like to point that 
in the Heinzel paper (178) only two HLA-E-restricted and TB-specific CD8 T cell clones 
were studied, both derived from one healthy LTBI subject, and cytotoxic activity of the 
clones was not assessed. 
Similarly, in the Joosten paper (179) only two of four tested HLA-E restricted CD8 T cell 
lines produced IFN-γ and all four lines killed BCG-infected targets but also exerted TGF-β-
mediated suppressive activities. None of the studies investigated the microbicidal properties 
of HLA-E-restricted CD8 T cells. In our studies, CD8 T cell lines were generated from 
patients with active TB and a total of 15 CD8 T cell lines were tested. Moreover, the 
cytokine producing profile of the T cell lines was also evident when CD8 T cells were 
stimulated ex vivo with HLA-E-binding Mtb peptides. 
Using HLA-E/peptide tetramers for four recognized HLA-E binding Mtb derived peptides, 
direct ex vivo recognition by TB patients’ CD8 T cells was demonstrated for all four 
epitopes and frequencies of peptide/tetramers in TB patients declined 6 months after the 
antimycobacterial therapy. One may speculate that expansion of HLA-E-restricted and Mtb 
specific CD8 T cells during active TB disease might be the consequence of active replication 
of Mtb residing in immature phagosomes. Since HLA-E is enriched within the Mtb 
phagosome, as compared to HLA class I molecules, the probability that endogenous 
peptides derived from Mtb could be presented to CD8 T cells in association with HLA-E 
molecules is very high during active TB disease but diminishes after successful therapy. In 
this case, the frequency of HLA-E-restricted/Mtb peptide specific CD8 T cells may be a TB-
specific biomarker of bacterial load during active infection, which is also rapidly regulated 
during successful chemotherapy. 
In conclusion, our studies have identified CD8 T cells from TB patients, which recognize 
Mtb derived peptides presented by HLA-E molecules, produce type 2 cytokines upon 
antigenic in vitro stimulation, mediate B cell help for Ab production, and have very limited 
TRAIL-dependent cytolytic activity and microbicidal potential toward Mtb infected human 
cell lines expressing HLA-E. These data, together with the finding that the frequency of 
HLA-E/Mtb peptide specific CD8 T cells declines after successful chemotherapy in TB 
patients withor without HIV co-infection, suggest that this is a new human T cell population 
involved in TB. 
Future studies are then needed to better dissect this HLA-E restricted response and to 
precisely determine the relative importance of effector/protective versus 
immunoregulatory/pathogenic mechanisms within this response during Mtb infection and 
disease. 
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Material and methods 
 
Human subjects 
Peripheral blood was obtained from 24 adults with TB disease (15 men, 9 women, age range 
42–61 years) from the Dipartimento di Medicina Clinica e delle Patologie Emergenti, 
University Hospital, Palermo, 15 LTBI subjects (10 men, 5 women, age range 38–59 years), 
and 10 tuberculin-negative healthy subjects (7 men and 3 women, age range 40–57 years). 
TB-infected patients had clinical and radiological findings consistent with active pulmonary 
TB (214). Diagnosis was confirmed by bacteriological isolation of Mtb in 14 patients. Other 
patients were classified as having highly probable pulmonary TB on the basis of clinical and 
radiological features that were highly suggestive of TB and unlikely to be caused by any 
other disease; the decision was made by the attending physician to initiate anti-TB 
chemotherapy, which resulted in an appropriate response to therapy. All patients were 
treated in accordance with Italian guidelines and received therapy for 6 months. Treatment 
was successful in all participants all of whom completed the full course of anti-TB 
chemotherapy, as shown by the absence of any clinical or radiographic evidence of recurrent 
disease and sterile mycobacterial cultures. Peripheral blood was collected before (TB0) and 
4 (TB4) and 6 months after completion of chemotherapy (TB6). None of the TB patients had 
been vaccinated with BCG, or were being treated with steroid or other immunosuppressive 
or antitubercular drugs at the time of their first sampling. Three patients had evidence of 
HIV infection. Tuberculin (PPD) skin tests were considered positive when the in duration 
diameter was larger than 10 mm at 72 h since injection of 5 U of PPD (Statens Serum 
institut, Copenhagen, Denmark). Individuals with LTBI were defined as healthy people with 
apositive tuberculin (PPD) skin test and no symptoms and signs of active TB (215). 
However, because the response to QuantiFERON TB Gold test was found in 73% (11/15) of 
PPD-positive LTBI subjects, only those 11 subjects positive to QuantiFERON TB Gold test 
were considered as being latently infected and were included in the study. All of the LTBI 
subjects were health-care workers, and thus very likely to be close contacts of TB index 
cases. Moreover, none of the LTBI subjects included in this study had been vaccinated with 
BCG. 
 
Ethics statement 
The study was approved by the Ethical Committee of the University Hospital, Palermo, 
where the patients were recruited. The study was performed in accordance to the principles 
of the Helsinki Declaration and those of the “Good Clinical Practices,” and all individuals 
gave written informed consent to participate. 
 
Peptide-HLA-E binding assays 
Murine TAP2-deficient T cell lymphoma RMA-S-cell line co-transfected with human β2-
microglobulin and HLA-E*01033 allele (RMA-S/HLA-E, kindly provided by J. E. Coligan, 
Laboratory ofImmunogenetics, NIAID, Rockville, MD, USA) was used in the experiments. 
RMA-S/HLA-E cells were resuspended in complete Roswell Park Memorial Institute 
medium at 1 x 106 cells/mL and incubated either alone or in the presence of the synthetic 
peptides (200 μM). The Mtb derived peptides used in these experiments are derived from 
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(179) and are listed in Table 1. The canonical VMAPRTLIL peptide sequence, identical to 
that present in most HLA-C alleles (199), was used as a positive control in binding 
experiments. After an overnight incubation at 37°C, cells were washed with PBS to remove 
free peptides. Next, HLA-E surface expression was monitored after staining with the anti-
HLA class I mAb A6.136 (IgM, produced in our laboratory) followed by appropriate PE-
conjugated goat antimouse Ab.  
 
CD8 T cell proliferation induced by Mtb peptides 
PBMCs were labelled with CFSE (5 mM, Molecular Probes, Eugene, OR, USA) and 105 
cells were stimulated with Mtb derived HLA-E-binding peptides at a concentration of 10 
μg/mL in complete RPMI 1640 medium (Euroclone, Devon,UK) supplemented with 10% 
heat-inactivated pooled human AB+ serum, 2 mM L-glutamine, 20 mM HEPES, 100 U/mL 
penicillin, 100 μg/mL streptomycin, and 5 x 10−5 M 2-mercaptoethanol (complete medium) 
in the presence of 5 ng/mL IL-7 (Peprotech,Rocky Hill, NJ, USA), as described in (179). 
Positive (PHA, 1μg/mL; Life Technologies, Paisley, UK) and negative (medium only) 
controls were included in each assay. On day 7 of culture, cells were harvested, replicates (n 
= 6) pooled and stained using CD3-PerCP, CD8-APC, and CD56-PE (BD Biosciences, San 
Jos´e,CA, USA) before acquisition on a FACSCalibur using CellQuestPro software (BD 
Biosciences). To analyze proliferation, cells were gated on lymphocytes, followed by gating 
on CD3+CD8+CD56− cells. The percentage ofproliferation was calculated using geometric 
means by subtracting the geometric mean of all cells from the geometric mean of the 
undivided population. Subsequently, the percentage was calculated by the following: (delta 
geo mean of sample − delta geo mean of negative control)/delta geo mean of maximal 
proliferation (179). 
 
Isolation and culture of NK cells 
NK cells from healthy donors were isolated using the Rosette Sepmethod (Stem Cell 
Technologies, Vancouver, BC, Canada). Only those populations displaying >95% of 
CD56+CD3− NK cells were selected. Purified NK cells were then cultured on irradiated 
feeder cells in the presence of 2 μg/mL PHA and 100 U/mL IL-2 (Proleukin, Novartis 
Pharma AG, Basel, Switzerland) to obtain, after limiting dilution, clonal NK cells. 
Proliferating NK-cell clones were selected on the basis of the expression of either 
CD94/NKG2A or CD94/NKG2C receptors as determined by flow cytometric analysis with 
the Z270 mAb (IgG1, anti-NKG2A produced in our laboratory) and the 1381 mAb (IgG2b, 
anti-NKG2C, R&D Systems, Minneapolis, MN, USA). To analyze the surface markers of 
NK-cell clones, cells were incubated with mAbs followed by PE-conjugated isotype-specific 
goat antimouse second reagents (Southern Biotechnology Associates, Birmingham, AL, 
USA). Samples were analyzed on a FACSCalibur with the CellQuest program (BD 
Biosciences). 
 
NK-cell cytolytic activity 
NK-cell clones were tested for cytolytic activity in a 4-h 51Cr release assay as described 
(216) in the presence or absence of anti-CD94 mAb Y9 (IgM, 10μg/mL). Target cells used 
in these experiments were RMA-S/HLA-E (described above) and the human 
erythroleukemic cell line K562 transfected with HLA-E*0103(K562/HLA-E, kindly 
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provided by E. H. Weiss, Department of Biology, Anthropology and Human Genetics, 
Ludwig-Maximilians-Universitat, Munich, Germany) (217). Target-cell lines were 
previously incubated overnight at 37°C, either alone or in the presenceof the synthetic 
peptides (200 μM). Peptides were kept throughout the assay to assure higher levels of HLA-
E expression. E:T ratios used in experiments are indicated in figures. 
 
Generation of CD8 T cell lines and functional assays 
PBMCs from TB patients were cultured with 10 μg/mL of Mtb derived peptides at 3 x 106 
cells/well in complete medium and human recombinant IL-2 (40 U/mL) (218). Every 3 days, 
the culture was refreshed by medium plus IL-2 (40 U/mL). After 15 days, cultures were 
restimulated weekly with an equal number of peptide-pulsed irradiated (120 Gy from a 
Caesium source) K562/HLA-E cells, in the presence of 40 U/mL IL-2 and 15ng/mL IL-15. 
After four to five cycles of restimulation, the enriched population contained >80% CD8+ T 
cells (also see Table 2). Cells were restimulated weekly as described earlier. CD8 T cell 
lines were analyzed in detail by flow cytometry. Fluorochrome-conjugated antibodies used 
for staining included CD3 (HIT3a or SK-7, BD Biosciences), CD8 (RPA-TB or SK1, BD 
Biosciences), CD45 (2D1, BD Biosciences), CD56 (B159, BD Biosciences), CD94 (HP-
3D9, BD Biosciences), CD16 (3GB, BD Biosciences),TCRαβ (WT31, BD Biosciences), 
NKG2A (134111, R&DSystems), NKG2C (1381, R&D Systems), Granzyme B (GB11, 
BDBiosciences), rabbit anti-human granulysin (a kind gift of Dr. A.Krensky, Stanford, CA, 
USA) in combination with goat-anti-rabbit FITC (BD Biosciences), TRAIL (RIK-2, 
eBioscience), perforin (dG9, eBiosciences), or isotype-control mAbs. 
Samples were acquired on a FACSCanto and analyzed using FACSDiva software (BD 
Biosciences). Scoring was based on the percentage of cells that expressed the particular 
marker, and markers expressed by 10% of the cells, or more, were considered positive. 
The gating strategy is shown in Supporting Information Figure 6. 
For functional assays, cells were maintained for 1 week without restimulation (i.e. only with 
IL-2 and IL-15) before assays were done. CD8+ T cells (5 x 104) were incubated with K562 
orcK562/HLA-E cells in the presence or absence of synthetic peptides. After 24 h, the 
supernatants were collected and stored at −70° C until testing. Cytokine levels (TNF-α, IFN-
γ, TGF-β, IL-2, IL-4, IL-5, IL-10, IL-13, IL17, and IL-22) were assessed by ELISA (R&D 
Systems). In some experiments, cocultures were carried out inthe presence of blocking 
mAbs to HLA-E (3D12, BioLegend, San Diego, CA, USA), HLA-A/B/C (G46-2.6, BD 
Biosciences), anti-HLA Class I monomorphic (MEM-147, from Prof. V. Horejsi, Institute of 
Molecular Genetics, Prague, Czech republic), anti-CD3 (blocking, MEM-57 from Prof. V. 
Horejsi), anti-TCR αβ (WT31,BD Biosciences), CD8 (RPA-TB, BD Biosciences), NKG2D 
(1D11, eBioscience, San Diego, CA), NKG2C (1381, R&D Systems), CD94 (HP-3D9, BD 
Biosciences), or isotype-matched mAbs at 10 μg/mLfinal concentrations. The cytotoxic 
activity of CD8 T cell lines was assessed following 6-h incubation with unpulsed or peptide-
pulsed K562 or K562/HLA-E target cells at an E:T ratio of 10:1. Evaluation of dead cells 
was performed by flow cytometry after incubation with annexin-V-FLUOS staining kit 
(Roche Diagnostics, Milan, Italy) for the detection and quantification of apoptosis and 
differentiation from necrosis at single cell level, based on Annexin-V-labeling. In some 
experiments, cytotoxic assay was carried out in the presence mAbs to FasL (CD95L, 2C101, 
Vinci Biochem, Firenze, Italy), TNF-α (Infliximab, a gift of Prof. G. Triolo, Dipartimento 
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Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy), or 
TRAIL receptors 1 (DR4) and 2 (DR5), both provided by Dr. H. Walczak (Tumor 
Immunology Unit, Division of Medicine, Imperial College, London, UK). To inhibit 
perforin-mediated cytotoxicity CD8 T cell lines were incubated with CMA (Sigma, St. 
Louis, MO, 15 nM final concentration) for 30 min at 37°C prior to coculture, without further 
washing. Pre-treatment of CD8 T cell lines with CMA at the concentration used in this study 
did not have any cytotoxic effect. Cytotoxicity of Mtb cells and assessment of viability of 
Mtb THP-1-, K562-, and K562/HLA-E-cell lines were infected for 24 at 37°C, 5% CO2 
with single-cell suspensions of Mtb H37Rv strain at a multiplicity of infection of 10. The 
infection was carried out in the absence of antibiotics, and post treatment, cells were washed 
with PBS to eliminate extracellular bacteria. Viability of infected cells was determined by 
trypan blue exclusion. Infected or uninfected THP-1-cell line and K562/HLA-E cells were 
extensively washed and added to peptide-specific CD8 T cell linesat an E:T ratio of 10:1. 
After 6h of co-culture, cytotoxicity of target cells was assessed by flow cytometry, as 
previously described, after incubation with annexin-V-FLUOS staining kit (Roche 
Diagnostics). Mtb infected THP-1-, K562-, and K562/HLA-E-celllines were incubated with 
peptide-specific CD8 T cell lines for 20 h at 37°C as described above, washed three times to 
eliminate bacteria that were not cell associated, lysed with 0.1% saponin, and sonicated for 
20 s. Serial tenfold dilutions were made in 7H9 broth and plated on 7H10 agar plates. Plates 
were sealed in plastic, kept at 37°C, and the number of colonies (CFUs) was counted 
after14–21 days (219). 
A human HLA-A*0201-restricted CD8 T cell clone specific for Mtb Ag 16-kDa120-128 
(218) was used as a positive control. 
 
Intracellular cytokine staining 
PBMCs (106/mL) were stimulated with peptides in the presence of monensin for 6 h at 37°C 
in 5% CO2. The cells were harvested, washed, and stained with anti-CD8 mAb (RPA-TB, 
BDBiosciences) in incubation buffer (PBS-1% FCS-0.1% Na azide) for 30 min at 4°C. The 
cells were washed twice in PBS-1% FCS and fixed with PBS-4% paraformaldehyde 
overnight at 4°C. Fixation was followed by permeabilization with 1% PBS, 0.3% FCS, 0.1% 
saponin, and Na azide for 15 min at 4°C. Staining of intracellular cytokines was performed 
by incubation of fixed permeabilized cells with anti-IFN-γ (25723.11, BD Biosciences), 
anti-IL-2 (MQ1-17H12, BD Biosciences), anti-TNF-α (MAb11, BD Biosciences), anti-IL10 
(BT-10, eBioscience), anti-IL-17A (eBio64DEC17, eBioscience), anti-IL-4 (BD 
Biosciences, 3010.211), anti-IL13 (Biolegend,JES10-5A2) mAbs or isotype-matched control 
mAbs. Cells were acquired and analyzed by FACS as described above. Analysis was 
performed on a minimum of 100 000 CD8 events acquired for each sample. 
Negative controls were obtained with CD8 T cell lines incubated with medium, in the 
absence of any stimulant. Cut-off values for a positive response were predetermined to be in 
excess of 0.01% responsive cells (197, 203). Results below this value were considered 
negative and set to zero (197, 203). 
 
Tetramer staining 
Tetramer staining was carried out as described in detail previously (197, 203, 220). PBMCs 
(106/mL) were incubated in U-bottom 96-well plates, washed twice in PBS containing 1% 
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FCS (Sigma), and stained for 30 min at 4°C with PE-labeled tetramers (5 μLeach) prepared 
as previously described (197, 203, 220); they were washed and subsequently stained with 
FITC-labeled anti-CD8 mAb (RPA-TB, BD Biosciences) and analyzed by flow cytometry 
on a FACSCanto. Data were analyzed with the use of FACSDiva (BDBiosciences). Viable 
lymphocytes were gated by forward and side scatter and the analysis was performed on 
100000 CD8 events acquired for each sample. A cutoff of 0.01% was used as described 
previously (197, 203); values below this were set to zero. 
 
Ab production in vitro. 
CD8 T cell help in Ab production was studied according to (221). HLA-E-restricted CD8 T 
cell lines or CD8 T cells isolated from the PBMCs of healthy donors were cocultured with 
sorted tonsillar B cells in 96-well plates at 105 cells/well each of T and B cells, in RPMI 
1640 medium supplemented with 10% heat inactivated FCS, 2 mM L-glutamine, 20 nM 
HEPES, and 100 U/mL penicillin/streptomycin. Ten days later IgG and IgM levels in the 
culture supernatants were determined by ELISA. 
 
Statistics 
Nonparametric Mann–Whitney U test was used to determine statistical differences in the 
distribution of the results. Values of p < 0.05 were considered significant. Data were 
analyzed using statistical software SYSTAT 11 (Systat Software). 
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 Supporting Informations 
 
 
 
 
Supporting Information Table 1. Characteristics of HLA-E-binding Mtb derived peptides. Mtb-derived 
peptides containing HLA-E binding motifs were selected from (179). Peptide sequences are indicated, as well 
as their originating proteins (Mtb Rv numbers and their Swissprot accession numbers). Peptides further 
selected in this study are indicated in bold.1UniProtKB/ Swissprot accession number. 2Binding was calculated 
as the concentration (μM) of peptide required to reduce fluorescence intensity of the standard peptide with 50% 
(IC50, (177)). 3Stabilization is expressed as MFI (see Materials and Methods). 
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Supporting Information Figure 1. Ability of Mtb peptides to stabilize HLA-E cell surface expression and to 
induce CD8 T cell proliferation. In (A) RMA-S/HLA-E cells were pulsed with the indicated peptides and were 
analyzed by flow cytometry for cell surface HLA-E expression. Each column shows the difference in MFI 
between anti-HLA class I A6.136 mAb and isotype-control mAb. Each value represents the mean ± SEM of 
three experiments. Peptide numbers are listed in Table 1. Negative control consisted of unpulsed RMA-
S/HLA-E cells and positive controls consisted of RMA-S/HLA-E cells pulsed with the HLA-C signal peptide 
(HLA-Csp) VMAPRTLIL. In (B), PBMC from 10 patients with active TB were stimulated with Mtb-derived 
peptides, as indicated in Materials and Methods. Peptide-induced CD8 T cell responses were scored positive 
when exceeding 10% proliferation in the absence of peptide. The frequency (%) of responder TB patients is 
shown. *p < 0.001 when compared to the No peptide group, as calculated by the Mann-Whitney U test. 
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Supporting Information Table 2. Phenotype of HLA-E-binding Mtb peptide-specific T cell lines. Numbers 
indicate the percentage (SD less that 15%) of positive cells. Markers expressed by more than 10% of cells are 
indicated in bold. *GrB = Granzyme B; Per = Perforin; Gra = Granulysin. 
 
 
Supporting Information Figure 2.Surface phenotype of Mtb peptide specific and HLA-E-restricted T cell 
lines. T cell lines were generated as described in Materials and Methods and cells were surface stained for 
several different markers. Representative overlay histograms showing surface markers expression on gating on 
CD3+ CD8+ T cells (open histograms) against appropriate control Ig isotypes (filled histograms). 
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Supporting Information Figure 3. Control for antibody inhibition activity. In (A), the NKG2C+ NK clone 
41.3 was tested for killing of RMA-S/HLA-E target cells in the presence of the indicted mAbs or isotype 
control mAb. In (B) the HLA-A*0201-restricted CD8 T cell clone specific for M. tuberculosis antigen 16-
kDa120-128, was tested for killing of Mtb infected THP-1 macrophage cell line, in the presence of the indicated 
mAbs or isotype control mAb. Data are mean ± SD of two different experiments carried out in triplicate. *p < 
0.001 when compared to control mAb, as calculated by the Mann-Whitney U test. 
 
 
 
Supporting Information Figure 4. Cytokine production by PBMC from TB patients stimulated ex vivo with 
HLA-E-binding Mtb peptides. PBMC (106/mL) from TB patients were stimulated with the Mtb peptide 68 for 
6 hrs, and stained for intracellular cytokines, as described under Materials and Methods. Shown are data from 7 
different TB patients (left) and FACS plot from two TB patients (right). 
 53 
 
 
Supporting Information Figure 5.Mechanism of killing of CD8 T cells recognizing Mtb peptides in the 
context of HLA-E. Three different HLA-E-restricted Mtb peptide-specific CD8 T cell lines were incubated 
with specific peptide-pulsed K562/HLA-E target cells. Cytotoxic activity toward targets was assessed after 6 
hrs coculture, in the presence of blocking mAbs to TNF-α, FasL, TRAIL-R1 and -R2, or CMA. Data are shown 
as mean ±SD of five different experiments carried out in triplicate. *p < 0.001 when compared with 
cytotoxicity carried out in the absence of inhibitors (isotype control mAb), as calculated by the Mann-Whitney 
U test. 
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Supporting Information Figure 6. Gating strategy used to analyze expression of surface markers, tetramer 
binding and intracellular cytokines in populations of CD8 T cells. Starting from the upper left, arrows indicate 
directionality of subgates. Markers are indicated to the left and bottom of each dot plot. 
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type 2 CD8+ T cells. 
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Results 
 
Frequency of HLA-E-restricted CD8+ T cells before and after Mtb peptide-
specific stimulation 
 
Recently Van Meijgaarden et al. (222) have demonstrated that Mtb-specific and HLA-E 
restricted CD8+ T cell clones derived from PBMC of healthy PPD+donors uniquely produce 
Th2(IL-4, IL-5, IL-13) cytokines following peptide stimulation, confirming the previously 
discussed data (Chapter 2).The presence of HLA-E-restricted Mtb peptide-specific CD8+ T 
cells was confirmed in the peripheral blood of TB patients during active disease. HLA-E 
tetramers containing peptide 62 and peptide 68 were recognized by an average of 0.28% and 
0.32% CD8+ T cells, respectively (Figure R1A). Moreover, PBMC obtained from TB patients 
showed little or no TNF- and IFN-γ  production, but produced significant levels of IL-4 and 
IL-13 after an overnight of Mtb-specific peptide stimulation in vitro (Figure R1B). 
 
 
 
Figure R1: CD8+ T cells from TB patients bind HLA-E/peptide tetramers and produce Th2 cytokines 
following peptide stimulation (from Van Meijgaarden et al., 2015). 
PBMCs from patients with pulmonary TB were stained directly ex vivo with HLA-E/peptide tetramers and 
analysed by flow cytometry. Data are presented as the percentage tetramer positive cells within the CD8+ 
population. PBMCs were stimulated with either peptide 62 or peptide 68 for 16 hours in the presence of 
monensin. Cytokines were stained by intracellular staining followed by flow cytometric analysis. These data are 
depicted as percentage of CD8+ T cells. (A) Results of combined TM staining on PBMCs from TB patients for 
both tetramers containing P62 or P68, data are presented as percentage of CD8+ T cells. (B) Cytokine production 
by CD8+ T cells following stimulation with peptide 62 (left) and peptide 68 (right). Open circles represent 
patients with tetramer staining <0.1%, close circles represent patients with tetramer staining >0.1%. Groups were 
compared using a Mann-Whitney U test and obtained p<0.05 value was significant. 
 
Based on these results and given that HLA-E tetramers loaded with Mtb-derived peptides p62 
and p68 were avalaible, direct ex vivo recognition by CD8+ T cells was analysed in 7 
tuberculin-negative (PPD-) healthy subjects, 3 latent tuberculosis infection (LTBI) subjects, 
10 patients with active TB and 3 HIV-TB co-infected patients (for the characteristics of 
recruited subjects see Materials and Methods, Table M1). The analysis was performed for 
both p62 and p68 tetramers in the same staining, therefore the frequency of tetramer+ CD8+ T 
cells refers to the T cell subsets recognizing one or the other Mtb-specific peptide. Moreover, 
we successfully developed an innovative protocol which combines surface staining with 
HLA-E tetramers and intracellular staining (ICS) to analyse the functional property of 
A
.
.
. 
B
.
.
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antigen-specific HLA-E-restricted CD8+ T cells through a gating strategy. This novel method 
also allowed us to specifically select and analyze the tetramer+ CD8+ T cell subset (Figure R2, 
A).  
The ex-vivo frequency of tetramers-specific CD8+ T cell was higher in patients with TB active 
than in healthy PPD-control donors and this difference was statistically significant, despite the 
fact that relevant variability in the proportion of tetramer+CD8+ T cells was observed. As 
expected, the highest mean frequency of tetramer-specific CD8+ T cells was found in the 3 
HIV-TB patients (Figure R2, B). 
Given the low frequency of HLA-E-restricted and Mtb-specific CD8+ T, we performed a 
preliminary polyclonal activation with PHA to amplify the size of this CD8+ T cell pool.  
After 6 days of PHA stimulation, CD8+ T cells were sorted and were stimulated for one week 
in the presence of irradiated allogeneic feeder cells, the p62 and the p68 Mtb-specific peptides, 
and IL-2, IL-7 and IL15. Using this method, the size of Mtb peptide-specific CD8+ T cells 
escalated after Mtb-specific peptides stimulation, as shown by the large increase of the 
number of tetramer+ events. However, the ex vivo mean frequency of tetramer specific CD8+ 
T cells remained unchanged upon stimulationwith Mtb-specific peptides (0.52% versus 0.5%), 
clearly indicating that the in vitro stimulation with PHA and specific peptides did not 
introduce any bias in the obtained CD8+ T cell population (Figure R3, A and B and Table 
R1).  
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Figure R2: FACS dot plots of CD8+ tetramer+ T cells ex vivo and after Mtb-specific peptides stimulation. 
(A) Gating strategy was used to analyze expression of surface markers, tetramer binding and intracellular 
cytokines in population of tetramer+ CD8+ T cells. The dot plots represent each step of subgating. (B) 
Representative flow cytometry dot plots of a single active TB patient compared to a single PPD- healthy subject 
following staining with HLA-E tetramers containing both peptide 62 and peptide 68. Cells were gated on CD8+ 
T cells and showed before (on the top) and after Mtb-specific peptides stimulation (on the bottom). 
B
. 
A
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Figure R3: CD8+ tetramer+ T cells frequency ex vivo and after Mtb-specific peptides stimulation. 
(A and B): HLA-E-restricted CD8+ T cells displayed by frequency (A) and number of tetramer+ CD8+ events 
(B) and showed before (on the left-hand side) and after Mtb-specific peptides stimulation (on the right-hand 
side). Data are depicted as the percentage tetramer positive cells within the CD8+ population, as shown in Figure 
R2A. 
 
 
The mean frequency of tetramer specific CD8+ T cells in TB-HIV co-infected patients was 
1.16% and decreased to 0.23% after Mtb-specific peptides stimulation: exhaustion of CD8+ T 
cells in HIV-infected patients most likely accounts for the loss of CD8 T cells. The 
phenomenon of T cell exhaustion is well know in chronic viral infections such as HIV in 
which the lack of CD4+ T cells and the persistence of antigens can induce defects in memory 
T cell responses.  
Moreover the higher mean frequency of tetramers-specific CD8+ T cells in patients with 
active TB compared to LBTI subjects and healthy donors was confirmed, as previously 
described. The ex vivo frequency found in LTBI subjects was 0.19% decreasing to 0.12% after 
Mtb-peptide specific stimulation (Table R1). 
  
A
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Condition Healthy 
Donors 
LTBI Active TB HIV-TB 
ex-vivo 0.12 0.19 0.52 1.16 
After Mtb-peptides in 
vitro stimulation 
0.18 0.12 0.5 0.23 
 
Table R1:The mean frequency of tetramer specific CD8+ T cells. The table shows mean frequency of 
tetramer specific CD8+ T cells analyzed in the peripheral blood of 7 tuberculin-negative (PPD-) healthy subjects, 
3 latent tuberculosis infection (LTBI) subjects, 10 active TB and 3 HIV-TB co-infected patients. 
 
 
Phenotypic analysis of HLA-E-restricted CD8+ T cells before and after 
Mtb-specific peptidestimulation 
 
The phenotype of the total CD8+ T cells as well as of HLA-E/Mtb peptide tetramer+ CD8+  T 
cells was determined by analysis of CCR7 and CD45RA expression in 7 PPD- healthy 
subjects, 3 LTBI subjects, 10 patients with active TB and 3 HIV-TB co-infected patients by 
flow cytometry. 
Ex vivo analysis of total CD8+ T cells showed a consistent proportion of naïve cells in LTBI, 
active TB samples and healthy control donors, whereas cells with a TEMRA phenotype  
dominated the CD8+ population in TB-HIV co-infected patients.  
In all tested groups the effector memory compartment was most abundant upon stimulation by 
Mtb-specific HLA-E-restricted peptides, indicating progressive differentiation of CD8+ T 
cells after stimulation (Figure R4).   
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Figure R4: CD8+ T Memory T cell subset phenotype. (A) Ex vivo profile gated on total CD8+ T cells revealed 
a consistent proportion of precursor cells in active TB and LTBI samples and healthy control donors, whereas a 
TEMRA profile was the main phenotype of the TB-HIV co-infected CD8+ T cells. (B) The CD8+T effector 
memory compartment was the most representative subset upon p62 and p68 Mtb-specific peptides stimulation. 
 
 
Ex vivo analysis of tetramer-specific CD8+ T cells revealed a higher percentage of naïve 
subset in patients with active TB, LTBI subjects and healthy donors, while tetramer+ CD8+ T 
cell with a TEMRA phenotype were the main population in TB-HIV co-infected patients.  
Stimulation with Mtb-specific peptides caused a decrease of antigen-specific naïve CD8+ T 
cells in patients with active TB and healthy control donors, an increase in the effector memory 
compartment, in control donors and LTBI subjects and an increase in the TEMRA 
compartment in patients with active TB. 
Finally, in HIV-TB co-infected patients Mtb peptide stimulation in vitro caused an increase in 
effector memory and central memory compartments (Figure R5). 
 
A
. 
B
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Figure R5: Mtb-specific HLA-E-restricted CD8+ T cells memory phenotype. (A)The ex vivo analysis 
tetramers of specific CD8+ T cells phenotype revealed a higher percentage in naïve compartment for all active 
TB, LTBI, healthy control donors samples. In TB-HIV co-infected samples the main population is represented 
by a TEMRA phenotype. (B) An increase in the effector memory compartment was identified in active TB, 
LTBI samples and healthy control donors, while the active TB’s tetramer+ CD8+ T cells exhibited a related 
increase in the TEMRA compartment. A trend of increase in both effector memory and central memory 
compartments was also identified in HIV-TB co-infected samples. 
 
 
Functional properties of HLA-E-restricted and Mtb-specific CD8+ T cells 
To assess the functional profile of HLA-E-restricted and Mtb-specific CD8+ T cells, we 
stimulated the T cell lines with either p62 and p68 Mtb-specific peptides and tested their 
cytokines profile as well as cytotoxic molecules production by intracellular staining (see 
Figure R6).  
 
A
. 
B
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Figure R6: FACS dot plots of cytokine and transcription factors profile of HLA-E-restricted and 
Mtbspecific CD8+ T cells. Dot plot analysis of a healthy control donor (A) and an active TB sample (B) 
stimulated with p62 and p68 HLA-E-specific peptides. The percentages of tetramer+ CD8+ T cells expressing 
IFN, IL13, IL4, TNF, T-bet, gata-3 or FoxP3 are shown into the red quadrants of each FACS gate.  
 
 
Tetramer-specific CD8+ T cells produced Th2 cytokines, (particularly IL-4) (Figure R7). 
These results are consistent with the data reported in the study of Van Meijgaarden et al., in 
which peptide-specific HLA-E-restricted CD8+ T cell clones were characterized by IL-4 and 
IL-13 production following overnight stimulation with peptides p62 or p68.  
However, an unexpected production of IFN by tetramer specific CD8+ T cells was observed.  
We also assessed the expression of Th1-function associated T-bet, Th2-function associated 
GATA3 and regulatory-function associated FoxP3 transcription factors. Significative 
expression of the Treg specific transcription factor FoxP3 was found in tetramer+ CD8+ T 
cells from patients with active TB and LTBI subjects suggesting a possible regolatory role of 
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these cells. Notably, no expression of GATA3 was detected. Thus, some alternative 
mechanism has to be involved in IL- 4 and IL-13 expression that needs further investigation. 
In agreement with FN production, higher expression of the transcription factor T-bet (which 
is associated with Th1-function) was found  in tetramer+ CD8+ T cells from patients with 
active TB compared to healthy controls. 
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Figure R7: Cytokines and Transcription factors profile of total CD8+ T cell compartment and of Mtb-
specific HLA-E restricted CD8+  T cells. An intracellular staining for IFN, IL13, IL4, TNF and T-bet, gata-3 
or FoxP3 was assessed. In (A) is shown the cytokine profile evaluated in total CD8 and tetramer-specific CD8 T 
cells and  in (B) the transcription factors profile is evaluated as previously mentioned. 
 
 
Further analysis of cells with a polyfunctional profile showed no significative difference 
between healthy controls and patients with active TB either in the total CD8+ T cell 
compartment or in the tetramer+ CD8+ T cells (Figure R8). 
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Figure R8: Polyfunctional cytokine profile of total CD8+ T cell compartment and of Mtb-specific HLA-E 
restricted CD8+ T cells. The simultaneous analysis of IFN, IL13, IL4, TNF was assessed for total CD8+ T 
cells (A) and of tetramer+ CD8+ T cells (B) using FlowJo’ Boolean gating tool. No evident differences between 
healthy control and active TB CD8+ T cells in multiple cytokines expression were observed, although in the 
tetramer+ CD8+ T subset an insignificant increase of T cells producing both IFN and IL-4 was detected in active 
TB subjects. 
B
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Several cytolitic molecules are produced by CD8 T cells in responce to Mtb infection, 
promoting host protection. These include Perforin and other molecules stored in granules such 
as Granzyme A, Granzyme B and Granulysin (223-227). Expression of Perforin, Granzyme 
A, Granzyme B and Granulysin was then analysed in the cohort of healthy subjects, LTBI 
subjects, patients with active TB and  HIV-TB co-infected patients (Figure R9). 
 
 
 
Figure R9: FACS dot plots of cytotoxic molecules profile of total CD8+ T cell subset and HLA-E-
restricted- Mtb specific CD8+ T cells. CD8+ T cells were stimulated for seven days with p62 and p68 HLA-E 
specific Mtb peptides and the expression of Perforin, Granzyme A, Granzyme B and Granulysin was assessed by 
flow cytometry. The dot plots are gated on total CD8+ T cell subset (on the top) and HLA-E-restricted- Mtb 
specific CD8+ T cells (on the bottom). 
 
In all tested samples, the cells expressed no cytotoxic molecule and no significant differences 
were found between healthy control, patients with active TB, LTBI subjects and HIV-TB 
coinfected patients, with the exception of Granzyme A production which was significantly 
increased in total CD8+ T cells from  patients with  active TB compared to healthy controls 
(p<0.02, Figure R10 A and B).  
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Figure R10: Cytotoxic potential of total CD8+ T cell compartment and of Mtb-specific HLA-E restricted 
CD8+ T cells. The histogram shows total CD8+ T cell subset (A) and HLA-E-restricted- Mtbspecific CD8+ T 
cells (B) expressing Perforin, Granzyme A, Granzyme B and Granulysin in healthy control, active TB, LTBI, 
HIV-TB samples, after p62 and p68 HLA-E Mtb peptides stimulation. 
 
Moreover, and interestingly, a decrease of total and Mtb-specific CD8+  T cells co-expressing 
Perforin, Granzyme B and Granulysin was detected in patients with active TB as compared to 
healthy controls (p<0.04 for total CD8+ T cells and p<0.015 for Mtb-specific CD8+ T cells; 
Figure R11 A and B respectively). In contrast, CD8+ T cells containing Granzyme A alone 
or in combination with other cytotoxic molecules were more represented in patients with 
active TB than in  healthy control, although differences were not statistically significant. 
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Figure R11: Cumulative analysis of  Perforin, Granulysin, Granzyme A and Granzyme B in total CD8+ T 
cell and Mtb-specific CD8+ T cell compartments. The cumulative analysis of all cytotoxic markers in both 
total CD8+ (A) and Mtb-specific CD8+T cell compartments (B) indicated a decrease of  T cells co-expressing 
Perforin, Granzyme B and Granulysin (p<0.04 for total CD8+ T cells and p<0.015 for Mtb-specific CD8+ T cells 
respectively). 
 
 
Generation of HLA-E-restricted Mtb-specific CD8 T cell clones 
 
To study in detail the function of HLA-E-restricted Mtb-specific CD8+ T cells, we generated 
clones from the CD8+ T cell lines previously described. In particular, CD8+ T cell lines from 
A
.  
B
.  
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two patients with active TB were selected on the basis of the best response/expression of Th2 
cytokines and were stained with PE-labeled tetramers and sorted by positive selection using 
anti-PE magnetic beads. This procedure enabled us to select and separate the TM+ cells from 
total CD8+ T cells (Figure R12). 
Sorted tetramer+ cells were used to generate clones by the limited dilution technique. A total 
12 clones were isolated from the two cell lines and stored in liquid nitrogen for future studies. 
 
 
 
Figure R12: FACS dot plots of HLA-E-tetramer+ CD8+ T cells. Cultures of purified CD8+ T cells were 
stained with PE-labeled tetramers and sorted by positive selection using anti-PE magnetic beads (MACS, 
Miltenyi Biotec). Dot plots in A, B and C show the tetramer+ CD8+ T subset before (A) and after MACS sorting, 
in particular the selected tetramer+ CD8+ T cells (B) and the leftover (C). In total 12 clones from two cell lines 
were isolated and frozen in nitrogen. (D) Image of one representative T cell clone obtained upon limiting 
dilution assay culture at 0.3 cell/well. 
 
Analysis of ex-vivo frequency of MAIT cells 
 
Recently there is a great deal of interest in studing Mucosal-Associated Invariant T (MAIT) 
cells because they exert an important antimicrobial role in infection models (228, 229). MAIT 
cells are characterized by the expression of a unique V7.2-J33/12/20 TCR together with 
additional surface markers such as CD26, CD161, IL-18R, and a range of chemokine 
receptors such as CCR6, CCR5, CCR9 and CXCR6, that promote their localization to gut, 
lungs and liver (230, 231, 232). MAIT cells are absent in the peripheral blood of  HCV- and 
HIV-infected patients (233, 234) and in these latter MAIT loss persists despite the successful 
anti-retroviral therapy (235, 236).  
Similarly, the frequency of MAIT cells is lower in the peripheral blood of patients with active 
TB, both with or without HIV co-infection, than in healthy controls (237, 238). A reduction in 
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circulating MAIT cells is also associated with aging and with alterations in cytokine profile 
(238).  
Using flow cytometry, we compared the ex vivo frequency of MAIT cells in 7 tuberculin-
negative (PPD-) healthy subjects, 3 LTBI subjects, 10 patients with active TB and 3 HIV-TB 
co-infected patients. MAIT cells were indentified by the simultaneous expression of V7.2 
TCR, CD161 and CD26, upon gating on total CD8+ T cells using the FlowJo’s Boolean 
gating tool which allows to see all possible Boolean combination gates of a population thanks 
to the possibility to select more than one specific cell marker at the same time (Figure R13A 
and B). As expected, MAIT cells are less represented in the peripheral blood of patients with 
active TB and TB-HIV co-infection, in comparison to healthy donors. The same finding was 
detected in LTBI subjects, although only three subjects were analysed (Figure R13 C). 
 
 
 
Figure R13: Ex-vivo analysis of MAIT compartment. Dot plots show the percentage of CD8+, CD161+ and 
V7.2 TCR+ T MAIT cells in one active TB patient (A) compared with a healthy donor (B). (C) Ex vivo MAIT 
frequency in 7 healthy control donors, 3 LTBI subjects, 10 active TB and 3 HIV-TB co-infected patients (graph 
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on the left) and amount of MAIT cells expressing PD-1 (graph on the right). MAIT cells were identified as 
CD8+, V7.2 TCR+, CD161+ and CD26++ using the FlowJo’s Boolean gating tool.  
 
T cell exhaustion is a hallmark of CD8+ T cells engaged in immune response in several 
chronic infections such as HIV, HCV and HBV (239). In addition, programmed cell death 
protein 1 (PD-1) has an important role in the exhaustion of classical CD8+ T cells in HIV 
infection (240). Therefore we should understand if there is an association between MAIT cells 
depletion in patients with TB and HIV/TB co-infections and the phenomenon of exhaustion of 
CD8+ T cells. However, we did not find significant increase in PD-1 expression on MAIT 
cells in patients with TB and HIV-TB co-infection (Figure 13C). 
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Materials and Methods 
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Recruited patients 
Peripheral blood was collected from 10 adults with TB disease, 3 adults with TB-HIV co-
infection and 3 LTBI subjects, from the Dipartimento di Medicina Clinica e delle Patologie 
Emergenti, University Hospital, Palermo whereas 7 tuberculin-negative PPD- healthy subjects 
were recruited from anonymous bloodbank donors in Netherlands (Sanquin Bloodbank, the 
Netherlands) (Table M1). The PBMCs of each patients was stored in nitrogen and, upon 
reaching a reasonable number of samples, the frozen samples were sent to the Department of 
Infectious Disease at Leiden University Medical Center (LUMC) in Leiden in which the 
experiments described below were assessed. 
 
Stage of 
disease 
Enrolled 
subjects 
Gender Year of birth Clinical characteristics Other information 
 
 
 
 
 
Active TB 
TB1 F / pulmonary TB mantoux positive 
TB2 M 1972 pulmonary TB mantoux positive 
TB3 M 1996 pulmonary TB mantoux positive 
TB4 M 1996 miliary TB mantoux positive 
TB5 F 1979 pulmonary TB mantoux positive 
TB6 F 1982 pulmonary TB mantoux positive 
TB7 M 1986 pulmonary TB mantoux positive 
TB8 M 1970 extra-pulmonary TB mantoux positive 
TB9 F 1972 pulmonary TB mantoux positive 
TB10 F 1982 pulmonary TB mantoux positive 
 
TB-HIV 
co-infection 
TB-HIV1 M 1983 miliary TB, HIV and HCV co-infection mantoux positive 
TB-HIV2 M 1969 miliary TB, HIV co-infection mantoux positive 
TB-HIV3 M 1979 miliary TB, HIV co-infection mantoux positive 
 
Latent TB 
LTBI-1 F 1954 No disease, LTBI mantoux positive 
LTBI-2 M 1960 No disease, LTBI mantoux positive 
LTBI-3 M 1960 No disease, LTBI mantoux positive 
 
 
 
Healthy donors 
(PPD-) 
HD-1    PPD- 
HD-2    PPD- 
HD-3    PPD- 
HD-4    PPD- 
HD-5    PPD- 
HD-6    PPD- 
HD-7    PPD- 
 
Table M1: Clinical characteristics of the subjects enrolled in the study.Peripheral blood was collected from a 
total of 16 subjects, 10 adults with active TB disease, 3 adults with TB-HIV co-infection and 3 adults with LTBI 
from the Dipartimento di Medicina Clinica e delle Patologie Emergenti, University Hospital, Palermo.The 7 
tuberculin-negative healthy donors included in the study were obtained from the anonymous Dutch bloodbank 
donors (Sanquin Bloodbank, the Netherlands), therefore no information about age, sex and clinical 
characteristics of the anonymous samples was available. For each healthy donors control the PPD- responce was 
assessed by IFN ELISA. 
 
Selection of PPD- healthy controls from bloodbank donor. 
Lymphocyte stimulation assays were performed stimulating PBMCs from the healthy donors  
(0,5x106/w) in 48-well plates with 5 μg/mL final concentration of PPD (Staten Serum 
Institute, Copenhagen, Denmark) in an incubator at 37°C with 5% CO2. Phytohemagglutinin 
(PHA, 5 μg/mL final concentration, Remel Europe), and unstimulated samples were used as 
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positive and negative controls, respectively. After 24hours and 7 days the supernatant were 
collected and then used to assess an IFN-ELISA (U-CyTech, Utrecht, the Netherland). 
 
Ex vivo surface tetramer staining 
HLA-E/Mtb peptide tetramers were used to assess the ex vivo frequency of HLA-E/peptide 
CD8+ T cells in the peripheral blood of 7 tuberculin-negative (PPD-) healthy donors, 3 LTBI 
subjects, 10 active TB patients and 3 HIV-TB co-infected patients.  
Peripheral blood mononuclear cells (PBMC, 106/mL) were isolated from heparinized blood 
samples by Ficoll-Hypaque (Pharmacy LUMC, the Netherland) density centrifugation, 
washed twice in phosphate buffered saline (PBS, Pharmacy LUMC, the Netherland) 
containing 0,1% BSA (Sigma), stained for 10 min at RT with a purified anti-CD94 mAb and 
then stained for 30 min at 4°C with PE-labeled tetramers in 5ml FACS tubes. For the 
characteristics of peptides used see Table M2. After the incubation the samples were washed 
with PBS (Pharmacy LUMC, the Netherland) containing 0,1% BSA (Sigma), and 
subsequently characterized by 11 different surface markers plus live/dead dye, with a 
combination of 12 colour fluorochromes (also see Table M3 in which the characteristics of 
mAb used are summarized) collected in the same panel. Live/dead stain (Vivid fixable violet 
reactive dye, Invitrogen, Thermo Fisher Scientific Inc.) was used for all samples according to 
the manufacturer’s protocol. Fluorochrome-conjugated antibodies used for staining included 
anti-CD3 (Horizon V500, UCHT1), anti-CD8 (AlexaFluor700, RPA-T8), anti-CD4 (PerCp-
Cy5.5, RPAT4) anti-CD45RA (BV570, MI100), anti-CCR7 (PE-Cy7, 3D12), anti-CD95 
(AlexaFluor647, DX2), anti-CD62L (Qdot605, DREG-56), anti-CD14 (Qdot655, TüK4),anti-
TCR Vα7.2 (APC-Cy7, 3C10), anti-CD161 (PE-Cy5, DX12), anti-CD26 (PE-C594, M-A261) 
mAbs. The samples were stained with for 30 min at 4°C, washed twice in PBS containing 
0,1% BSA and then aquired on a LSRFortezza flow cytometer with Diva software (v6.2, BD 
Biosciences).  
 
# Peptide 1 Amino acid 
sequence 
Derived 
from 
Amino 
acid 
position 
Protein name Accession 
number 2 
Binding 
(in M) 3 
62 RMPPLGHEL Rv2997 470-478 P49 protein O53244 4 
68 VLRPGGHFL Rv1523 251-259 Methyltransferase Q50584 1,8 
 
 Table M2: HLA-E-binding Mtb-derived peptides properties.  
1 Peptides containing HLA-E binding motifs were selected from Joosten et al., 2010. 2 UniProtKB/ 
Swissprot accession number. (www.uniprot.org ) 3 Binding was calculated as the concentration (mM) of 
peptide required to reduce fluorescence intensity of the standard peptide with 50% (IC50, Joosten et al., 
2001). 
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Table M3: FACS ex vivo analysis panel reporting surface markers, fluorochromes, clones, brand and 
related subset. 
 
Collected data were analyzed with the use of FlowJo software (version 9.7.3 Treestar Inc., 
Ashland, OR, USA). Scoring was based on the percentage of cells that expressed the 
particular marker. The analysis of each specific subset was performed using the gating 
strategy shown in Figure M1. After a previously selection of the singlet events, viable 
lymphocytes were gated by forward and side scatter and selected by the T cell co-receptor 
CD3. The analysis was performed on 100 000 CD8+ events acquired for each sample.  
  
ex-vivo PANEL 
SURFACE 
MARKERS 
FLUOROCHROM
ES 
CLONES BRAND SUBSET 
 
CD4 PerCp-Cy5.5 RPA-T4 BD Pharmigen CD4+ T cells 
PD1 AlexaFluor488 MIH4.1 BD Pharmigen Exaustion surface marker 
TCRV7.2 APC-Cy7 3C10 BioLegend MAIT 
CD8 AlexaFluor700 RPA-T8 BD Pharmigen CD8+ T cells 
CD14 Qdot655 TüK4 INVITROGEN Monocytes 
CD45RA BV570 MI100 BioLegend Phenotype analysis 
CD3 HorizonV500 UCHT1 BD Horizon Lymphoid region 
Vivid Pacific Blue   INVITROGEN live cells 
CCR7 PE-Cy7  3D12 BD Pharmigen Phenotype analysis 
CD161 PE-Cy5 DX12 BD Pharmigen MAIT 
CD26 PE-C594 M-A261 BD Horizon MAIT 
P62 and P68 
Tetramers 
PE   HLA-E resctricted CD8+ T 
cells 
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Figure M1: FACS ex vivo dot plots showing the gating strategy used for the identification of Total CD8+ T 
cells and Tetramers+ CD8+ T cells analysed. 
 
 
Generation of HLA-E restricted CD8+T cell lines 
PBMCs from 7 tuberculin-negative (PPD-) healthy donors, 3 LTBI individual, 10 active TB 
patients and3 HIV-TB co-infected patients were thawed (80% median viable cell yield), 
counted (CASY cell counter, Roche) and cultured in 24-well plates with Phytohemagglutinin 
(PHA, 5 μg/mL final concentration, Remel Europe), in complete Iscove’s modified 
Dulbecco’s medium (IMDM, Life Technologies-Invitrogen) added with 10% of human serum 
(pooled serum from blood bank donors) in an incubator at 37°C with 5% CO2. After 3 days, 
the growing cells were splitted and refreshed with human recombinant IL-2 (Proleukin, 
Chiron, Amsterdam, the Netherlands 25 U/mL final concentration). After 7 days of PHA 
polyclonal stimulation, the CD8+ T cells were sorted by positive selection using magnetic 
beads (MACS, Miltenyi Biotec BV, Leiden, the Netherlands). Purity of all cells sorts was 
checked by flow cytometry and resulted in  > 98% of purity.  CD8+ T cells sorted were 
subsequently cultured in presence of MtbP62- (RMPPLGHEL) and P68- (VLRPGGHFL) 
specific peptides (for peptide’s charactheristics see Table M1). Human recombinant IL-15 
and IL-7 (Peprotech, Rocky Hill, NJ both 5 ng/mL final concentration) have also been added 
as well as irradiated feeders cells (3600 rads for 4 minutes). After 24 h, the supernatants were 
collected and stored at −80°C. After 3 days, the culture was refreshed by complete IMDM 
medium plus IL-2 (50 U/mL). After 5 days, the cultures were splitted and refreshed with 
complete IMDM plus IL-2 (100 U/mL). After 7 days, the supernatants were collected and 
stored at −80°C.Starting with a number of  3-4x106 PBMCs, the yield of Mtb-specific CD8+ T 
cells after this procedure was about 80-100x106. 
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Intracellular staining (ICS) 
Cytokine, trascriptional factor and cytotoxic molecules profiles of the CD8+ T cells stimulated 
with Mtb-specific peptides were analysed followed by 16 hours incubation with BrefeldinA (3 
μg/ml, Sigma-Aldrich) and monensin (1:1000, BioLegend) at 37°C in 5% CO2. The cells 
were harvested, washed, and stained for 10 min at RT with a purified anti-CD94 mAb and 
then were stained with PE-labeled tetramers in 5ml FACS tubes and with anti-CCR7 (PE-
Cy7, 3D12) for 15 min at 37°C. After the incubation, the cells were washed once in PBS 
(Pharmacy LUMC, the Netherland) containing 0,1% BSA (Sigma) and subsequently 
characterized by 24 different markers with a combination of 15 colour fluorochromes (see 
Table M3 and M4 for the characteristics of mAb used) collected in two different panels of 14 
and 10 markers respectively for the analysis of cytokines/trascriptional factor, and cytotoxic 
molecules profiles. 
Fluorochrome-conjugated antibodies used for surface marker staining in the cytokine and 
trascriptional factors analysis comprised anti-CD3 (BV570, UCHT1), anti-CD8 (Horizon 
V500, RPA-T8), anti-CD25 (APC-H7, M-A251) and anti-CD45RA (BV570, MI100) mAbs, 
whereas in the cytotoxic molecules profile analysis were included anti-CD3 (BV570, 
UCHT1), anti-CD8 (Horizon V500, RPA-T8) and anti-CD45RA (BV570, MI100) mAbs. 
Live/dead stain (Vivid fixable violet reactive dye, Invitrogen, Thermo Fisher Scientific Inc.) 
was used for all samples according to the manufacturer’s protocol. 
Staining of intracellular cytokines was performed by fixing cells using FIX and PERM KIT 
according to the manufacturer’s protocol (BD Bioscence) and then by staining with anti-IFN-
γ (AlexaFluor700, B27), anti-IL-13 (APC, JES10-5A2), anti-TNF-α (PerCP-Cy5.5, MAb11), 
anti-IL4 (PE-C594), anti-GATA3 (AlexaFluor488, L50-823), anti-T-bet (BV605, 4BIO), anti-
FoxP3 (PE-Cy5, PCH101) mAbs. The samples were stained with for 30 min at 4°C, washed 
twice in PBS containing 0,1% BSA and then aquired on a FACS LSRFortezza flow cytometer 
with Diva software (v6.2, BD Biosciences).  
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Table M3: Trascriptional factor and cytokines analysis FACS panel reporting surface markers, 
fluorochromes, clones brand and related subsets. 
 
After the fixation and permeabilzation steps, the cells engaged for cytolytic molecules 
expression analysis were stained with rabbit-anti-human Granulysin (kind gift of Dr. A. 
Krensky, Stanford, CA) followed by Goat-anti-Rabbit-FITC, anti-Perforin (PEC594, 
δG9),anti-GranzymeB-(AlexaFluor700, GB11) anti-GranzymeA (PerCPCy5.5, CB9) mAbs 
and also an anti-IL10 (BV605, JES3-9D7) mAb was included.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table M4: Cytotoxic molecules analysis FACS panel reporting surface markers, fluorochromes, clones 
brand and related subsets. 
Transciptional Factors and Cytokines PANEL 
SURFACE 
MARKERS 
FLUOROCHROMES CLONES BRAND SUBSET 
 
TNF PerCp-Cy5.5 MAb11 BD Pharmigen Th1 -function associated 
GATA3 AlexaFluor488 L50-823 BD Pharmigen Th2-function associated 
CD25 APC-H7 M-A251 BD Pharmigen Treg-function associated 
IFN AlexaFluor700 B27 BD Pharmigen Th1-function associated 
IL13 APC JES10-5A2 BD Pharmigen Th2-function associated 
CD45RA Qdot655 MEM-56 INVITROGEN Phenotype  analysis 
T-bet BV605 4BIO BioLegend Th1-function associated 
CD3 BV570 UCHT1 BioLegend Lymphoid region 
CD8 HorizonV500 RPA-T8 BD Horizon CD8+ T cells 
Vivid Pacific Blue   INVITROGEN live cells 
CCR7 PE-Cy7  3D12 BD Pharmigen Phenotype analysis 
FoxP3 PE-Cy5 PCH101 Ebioscience Treg-function associated 
IL4 PE-C594 MP4-25D2 BD Horizon Th2-function associated 
P62 and P68 
Tetramers 
PE   HLA-E resctricted CD8+ T cells 
Cytotoxic T lymphocytes PANEL 
SURFACE 
MARKERS 
FLUOROCHROMES CLONES BRAND SUBSET 
 
Granzyme A PerCp-Cy5.5 CB9 BioLegend CTL -function associated 
Granulysin FITC     CTL-function associated 
Granzyme B AlexaFluor700 GB11 BD Pharmigen CTL-function associated 
CD45RA Qdot655 MEM-56 INVITROGEN Phenotype analysis 
IL10 BV605 JES3-9D7 BD Horizon 
anti-inflammatory function 
associated 
CD3 BV570 UCHT1 BioLegend Lymphoid region 
CD8 HorizonV500 RPA-T8 BD Horizon CD8+ T cells 
Vivid PB   INVITROGEN live cells 
CCR7 PE-Cy7 3D12 BD Pharmigen Phenotype analysis 
Perforin PE-C594 δG9 BD Horizon CTL-function associated 
P62 and P68 
Tetramers 
PE   HLA-E resctricted CD8+ T cells 
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Cells were acquired by FACS LSRFortezza flow cytometer as described above. Analysis of 
data was performed with FlowJo software (version 9.7.3 Treestar Inc., Ashland, OR, USA). 
Analysis was performed on a minimum of 2x106 CD8+ events acquired for each sample. 
Negative controls were obtained with CD8+ T cell lines incubated with medium without 
stimulant.  
 
Generation of HLA-E restricted CD8+ T cell clones 
CD8+ T cell lines from two active TB individual, generated as previously described  were 
cultured overnight in complete Iscove’s modified Dulbecco’s medium (IMDM, Gibco Life 
technologies, Thermo Fisher Scientific Inc), supplemented with 10% pooled human serum 
and were restimulated in 24 well plates with P62 and P68 Mtb-specific HLA-E-restricted 
peptides (5 μg/ml final concentration). The two CD8+ T cell lines were selected on the basis 
on the best responce/expression of Th2 cytokines profile. Cultures of purified CD8+ T cells 
were subsequently harvested and stained with PE-labeled tetramers (tetramers were folded at 
the facilities of the LUMC, Leiden) and were sorted by positive selection using anti-PE 
magnetic beads (MACS, Miltenyi Biotec BV, Leiden, the Netherlands). This procedure 
enabled us to select and separate the TM+ cells. Purity of all cell sorts was checked by flow 
cytometry and resulted in> 98% of purity.   
A limiting diluition assay was assessed with the sorted TM+ cells that were cultured in 96 well 
round bottom plates with descending cell density/well and with a feeder mixture providing 
irradiated feeders cells (3600 rads for 4 minutes, 5x104c/w), P62 and P68 Mtb-specific 
peptides (1μg/ml final concentration), in the presence of IL-7, IL-15 (Peprotech, Rocky Hill, 
NJ, both 5 ng/mL final concentration) and IL-2 (Proleukin, Chiron, Amsterdam, the 
Netherlands 50 U/mL final concentration). Every other day cells were splitted and freshed, 
IL-2 (100U/ml) was added. 
After two weeks of culture, growing clones were selected from the 0.3 c/well cultures and 
expanded as described above with alternating peptide pulsed irradiated feeders or T cell 
expander CD3/CD28 beads (Gibco Life Technologies, Thermo Fisher Scientifics Inc.). In 
total 12 clones from two cell lines were isolated and stored in nitrogen. 
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HLA-E-restricted CD8+ T lymphocytes as a new player in the 
adaptive immune response to Mycobacterium tuberculosis 
 
Over recent years it has become evident that many cellular subsets are involved in ensuring 
immune protection against pathogenic agents. Within adaptative immunity, the greatest group 
of CD4+ helper and CD8+ cytotoxic T cells are subdivided in several subsets each exerting 
different roles which includes pro-, anti- inflammatory and regulatory activities. These 
subsets can also differ significantly depending on tissue distribution. The homeostatic 
immune responses that work properly are implemented to maintain stability, expecially in 
case of chronic infections (241). 
As already discussed in Chapter 2,  non-classical MHC class I molecules such as HLA-E, can 
present peptides derived from several viruses and bacteria, including Mtb (178, 179) to CD8+ 
T cells, similarly to classical MHC class I molecules (180, 190, 204–208). 
 
Using a pool of Mtb peptides selected from a list previously characterized by Joosten et al. 
(179) we further screened these peptides for their capability to stabilize the HLA-E molecule 
on the surface of transfected cells, and to elicit a CD8+ T cells response. Five out of eighteen 
Mtb peptides were selected and were used in subsequent studies. HLA-E molecules are 
usually recognized by NK cells through the two CD94-NKG2A (inhibitory) or CD94-NKG2C 
(activatory) NK receptors. In order to exclude the recognition of HLA-E-Mtb peptide 
complexes by NK cells, experiments were conducted using NK cell clones selectively 
expressing the CD94-NKG2A inhibitory or CD94-NKG2C activatory receptors and target 
cells expressing HLA-E/Mtb peptides. Results obtained showed that there was no recognition 
of HLA-E/Mtb peptide complexes by NK-cell clones indicating that, although HLA-E/peptide 
complexes usually interact with the CD94-NKG2 NK receptors, HLA-E Mtb/peptide 
complexes do not engage NK receptors. Conversely, the five HLA-E/Mtb peptides are 
specifically recognized by CD8+ T cells in a CD3/TCR αβ mediated and CD8-dependent 
manner. 
 
CD8+ T cell lines derived from PBMC of patients with active TB secreted TNF-α, IL-4 and 
IL-13, either alone or in combination with IL-5, IL-10, and/or TGF-β, upon in vitro 
stimulation with specific Mtb peptides. The secretion of TGF-β suggests that a fraction of 
these cells might play regulatory activities, as shown by previous studies in TB (179). Very 
low or even no production of IFN-γ, IL-17, and IL-22 was detected. 
These results have been confirmed using an innovative protocol which combines HLA-E 
tetramer staining and intracellular staining (ICS) in CD8+ T cell lines obtained from PBMC of 
patients with active TB and TB-HIV co-infection, LTBI subjects and healthy donors, 
stimulated with two out of five Mtb peptides, p62 and p68. The ICS of tetramer-specific 
CD8+ T cells also revealed and confirmed the presence of an unusual Th2-type pattern of 
cytokine production. 
In a previous study Van Meijgaarden et al. found that HLA-E restricted CD8+ T cell clones 
derived from PBMC of healthy PPD+donors had a Th2 cytokine profile associated with the 
expression of the lineage-specifying transcription factor GATA3 (222). In contrast to these 
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data, in our experiments no expression of GATA 3 was detected. Furhter investigation is thus 
required to uncover mechanism responsible for this unexpected result. 
However, an unexpected production of IFN by tetramer specific CD8+ T cells was found. 
Again, at present we do not have any possible explanation for this finding and additional 
experiments are thus needed. Along with IFN production, also the lineage-specifying 
trascription factor T-bet associated with Th1 function had a greater expression in tetramer+ 
CD8+ T cells from patients with active TB, as compared to expression levels found in healthy 
controls. Surprisingly we also found a significant expression of the Treg specific transcription 
factor FoxP3 in HLA-E/Mtb peptide-reactive CD8+ T cell lines. These results imply a 
possible regolatory role of these cells.  
 
In addition to their unusual Th2 cytokine profile, HLA-E restricted CD8+ T cells have very 
poor cytolytic capacity. In particular, we found that only 3 of the 15 tested HLA-E-restricted 
Mtb-specific CD8+ T cell lines from patients with active TB were able to lyse target cells, at 
the same time demonstrating their impaired cytotoxic activity and their inability to inhibit 
Mtb outgrowth. 
An additional analysis of cytotoxic molecules profile was assessed in the same group of 
samples using ICS combined with tetramer staining. The simultaneous expression of perforin, 
granulysin, granzyme A and granzyme B was analysed. A significant increate expression of 
granzyme A was evident in total CD8+ T cells from patients with active TB compared to 
healthy donors. Conversely, HLA-E/Mtb-specific CD8+ T cells from different groups of 
patients and controls show similar granzyme A expression. A cumulative analysis of all 
cytotoxic markers in both total CD8+ and Mtb-specific CD8+ T cells revealed a significant 
decrease of T cells co-expressing perforin, granzyme B and granulysin in patients with active 
TB, compared to healthy controls.  
 
Finally, we studied ex vivo phenotypic analysis of tetramer-specific CD8+ T cells in the four 
tested groups. We found a higher percentages of naïve cells in patients with active TB, and in 
LTBI subjects and healthy donors, while in TB-HIV co-infected patients  the main population 
was represented by tetramer+ CD8+ T cells with a TEMRA phenotype. 
Moreover, we have evaluated the phenotype of these tetramer-specific CD8+ T cells upon 
stimulation with the peptides p62 and p68 for 7 days. The analysis of stimulated cells 
displayed an increase of cells with a TEMRA phenotype in patients with active TB and an 
increase of cells with effector memory and central memory phenotypes in the other tested 
groups. 
 
In conclusion, HLA-E-restricted CD8+ T cells specific for Mtb peptides represent a new 
effector T cells population in human TB, playing a role in immune response to active 
infection with Mtb. HLA-E/Mtb peptide-complexes are stable on the surface of transfected 
cells, induce proliferation of CD8+ T cells, and are specifically recognized by CD8+ T cells 
in a CD3/TCR αβ mediated and CD8-dependent manner. HLA-E-restricted CD8+ T cells are 
important part of the homeostatic immune response against Mtb. They elicit a Th2 response 
and possess potential regulatory function, demostrating that not only the canonical Th1 
responce is involved in the control of Mtb infection. Moreover, these cells have poor 
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cytolytic activity and microbicidal potential toward Mtbi nfected human cell lines 
expressing HLA-E molecule. 
Finally, the analysis of a new cellular subset such as MAIT cells was also investigated in our 
system. The innate anti-microbial activities exerted by these cells were already demostrated 
in murine model as well as in human (242). The comparison of the frequency of MAIT cells 
in peripheral blood of patients with active TB alone or in association with HIV co-infection 
revealed that MAIT cells are depleted from the blood in subjects with active TB or TB-HIV 
co-infected. This last aspect could be explained by a mechanism of cell exhaustion of 
constantly activated cells or their specific recruitment at the sites of infection.  
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